Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/10—Spiro-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D241/18—Oxygen or sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
  • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D241/20—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/10—Spiro-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/10—Spiro-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/07—Optical isomers

Definitions

• the present invention relates to compounds capable of inhibiting the activity of
• the invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
• Src Homolgy-2 phosphatase is a non-receptor protein tyrosine phosphatase encoded by the PTPNl 1 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3- kinase-AKT pathways.
• SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail.
• the two SH2 domains control the subcellular localization and functional regulation of SHP2.
• the molecule exists in an inactive, self -inhibited conformation stabilized by a binding network involving residues from both the N-SH2 and PTP domains. Stimulation by, for example, cytokines or growth factors leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.
• SHP2 myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
• SHP2 therefore, represents a highly attractive target for the development of novel therapies for the treatment of various diseases.
• the compounds of the present invention fulfill the need of small molecules to that inhibit the activity of SHP2.
• Ri is -XRi a ; wherein Ri a is selected from C 6- l oaryl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms or groups independently selected from N, C(O), O and S; wherein said aryl or heteroaryl of Ri a is substituted with 1 to 5 R 9 groups independently selected from halo, amino, hydroxy, N 3 , Ci -4 alkyl, dimethyl-amino, hydroxy-substituted-Ci -4 alkyl, halo-substituted-Ci -4 alkyl, amino-substituted-Ci- 4 alkyl, -C(0)ORio and -NHC(0)Rio; and X is selected
• R a and R ⁇ are independently selected from hydrogen, halo, carbonyl, Ci- alkyl, Ci- alkoxy, amino, hydroxy, C 3- scycloalkyl and Ci -4 alkyl-amino
• Rs a and Rs b are independently selected from hydrogen, carbonyl, Ci -4 alkyl, Ci -4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and Ci -4 alkyl-amino; wherein any two groups selected from R 2a , R2b, R3a, R-3b, Rta, R*, Rsa, Rsb and R 7 can form a 5 to 6 member unsaturated or partially saturated ring;
• Rg is selected from hydrogen, halo, cyano, Ci -4 alkyl, Ci.
• R ⁇ 5 a and R3 ⁇ 4 are independently selected from hydrogen and Ci- alkyl; R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain 1 to 3 heteroatoms or groups independently selected from N, C(O), 0 and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with 1 to 3 groups independently selected from
• the present invention provides a pharmaceutical composition which contains a compound of Formula I or a N-oxide derivative, tautomer, individual isomers and mixture of isomers thereof; or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.
• the present invention provides a method of treating a disease in an animal in which modulation of SHP2 activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof, or a pharmaceutically acceptable salt thereof.
• the present invention provides a method of treating a disease in an animal in which modulation of SHP2 activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the diseases, which method comprises administering to the animal a therapeutically effective amount of a compound of Formula I or a N-oxide derivative, individual isomers and mixture of isomers thereof, or a pharmaceutically acceptable salt thereof, in simultaneous or sequential combination with an anti-cancer therapeutic.
• the present invention provides the use of a compound of
• the present invention provides a process for preparing compounds of Formula I and the N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixture of isomers thereof, and the pharmaceutically acceptable salts thereof.
• alkyl refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 20 carbon atoms. Unless otherwise provided, alkyl refers to hydrocarbon moieties having 1 to 7 carbon atoms (Ci -7 alkyl), or 1 to 4 carbon atoms (Ci -4 alkyl).
• alkyl include, but are not limited to, methyl, ethyl, «-propyl, zso-propyl, «-butyl, sec- butyl, z ' sobutyl, ferr-butyl, «-pentyl, isopentyl, neopentyl, «-hexyl, 3-methylhexyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, «-heptyl, «-octyl, «-nonyl, «-decyl and the like.
• a substituted alkyl is an alkyl group containing one or more, such as one, two or three substituents selected from halogen, hydroxy or alkoxy groups.
• Halo-substituted-alkyl and halo-substituted-alkoxy can be either straight-chained or branched and includes, methoxy, ethoxy, difluoromethyl, trifluoromethyl, pentafluoroethyl, difluoromethoxy, trifluoromethoxy, and the like.
• Aryl means a monocyclic or fused bicyclic aromatic ring assembly containing six to ten ring carbon atoms.
• aryl may be phenyl or naphthyl, preferably phenyl.
• Arylene means a divalent radical derived from an aryl group.
• Heteroaryl is as defined for aryl above where one or more of the ring members is a heteroatom.
• Cs-ioheteroaryl is a minimum of 5 members as indicated by the carbon atoms but that these carbon atoms can be replaced by a heteroatom.
• C5-ioheteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo[l,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, thienyl, etc.
• Cycloalkyl means a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing the number of ring atoms indicated.
• C 3- i 0 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, etc.
• Heterocycloalkyl means cycloalkyl, as defined in this application, provided that one or more of the ring carbons indicated, are replaced by a moiety selected
• C3- 8 heterocycloalkyl as used in this application to describe compounds of the invention includes morpholino, pyrrolidinyl, pyrrolidinyl-2-one, piperazinyl, piperidinyl, piperidinylone, l,4-dioxa-8-aza-spiro[4.5]dec-8-yl, thiomorpholino, sulfanomorpholino, sulfonomorpholino, etc.
• Halogen (or halo) preferably represents chloro or fluoro, but may also be bromo or iodo.
• SHP2 means "Src Homolgy-2 phosphatase” and is also known as SH-PTP2,
• Cancers harboring "PTPN11 mutations” include but are not limited to: N58Y;
• D61Y, V; E69K; A72V, T, D; E76G, Q, K ALL
• Compounds of formula I may have different isomeric forms.
• any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration.
• the compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as pure diastereomers or pure enantiomers.
• a compound does not exclude that (e.g. in a pharmaceutical formulation) more than one compound of the formula I (or a salt thereof) is present, the "a” merely representing the indefinite article.
• A can thus preferably be read as “one or more", less preferably alternatively as “one”.
• the term "and/or an N-oxide thereof, a tautomer thereof and/or a (preferably pharmaceutically acceptable) salt thereof especially means that a compound of the formula I may be present as such or in mixture with its N-oxide, as tautomer (e.g. due to keto-enol, lactam-lactim, amide-imidic acid or enamine-imine tautomerism) or in (e.g. equivalency reaction caused) mixture with its tautomer, or as a salt of the compound of the formula I and/or any of these forms or mixtures of two or more of such forms.
• tautomer e.g. due to keto-enol, lactam-lactim, amide-imidic acid or enamine-imine tautomerism
• equivalency reaction caused mixture with its tautomer
• the NH2 group attached to the pyrazine ring is critical for potency.
• Analysis of the crystallographic structure shows the NH2 group in an intramolecular interaction with the backbone carbonyl group of SHP2 residue E250:
• the present invention also includes all suitable isotopic variations of the compounds of the invention, or pharmaceutically acceptable salts thereof.
• An isotopic variation of a compound of the invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
• isotopes that may be incorporated into the compounds of the invention and pharmaceutically acceptable salts thereof include, but are not limited to, isotopes of hydrogen, carbon, nitrogen and oxygen such as as 2 H, 3 H, n C, 13 C, 14 C, 15 N, 17 0, 18 0, 35 S, 18 F, 36 C1 and 123 I.
• isotopic variations of the compounds of the invention and pharmaceutically acceptable salts thereof are useful in drug and/or substrate tissue distribution studies.
• 3 H and 14 C isotopes may be used for their ease of preparation and detectability.
• substitution with isotopes such as 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements.
• Isotopic variations of the compounds of the invention or pharmaceutically acceptable salts thereof can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
• a compound of the invention can exist in a deutorated form as shown below:
• the present invention relates to compounds capable of inhibiting the activity of
• -XRi a is -SRi a and is selected from:
• n is selected from 1, 2, 3 and 4; p is selected from 0 and 1; q is selected from 0 and 1 ; Yi is selected from CH and N; Y 2 is selected from C 5 and N; Y 4 is independently selected from N, C(O) and CRg; wherein only one Y4 is C(O); 5 is selected from hydrogen, halo, methyl and amino-carbonyl; R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, 0 and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with a group selected from amino, amino-methyl and methyl-amino; R 9 is selected from halo, amino, dimethyl-amino, hydroxy, N 3 , Ci -4 alkyl, halo-substituted
• R 7 and R 8 together with the carbon atom to which they are both attached form a 5 member saturated or partially unsaturated ring that can optionally contain 1 to 2 heteroatoms or groups independently selected from N, O, C(O) and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with 1 to 3 groups independently selected from amino, hydroxy, methoxy, halo, methyl, methyl-amino and isobutyryloxy; or a pharmaceutically acceptable salt thereof.
• R 7 and R 8 together with the carbon atom to which they are both attached form a 6 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, 0 and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R7 and Rs is substituted with a group selected from amino, amino-methyl and methyl-amino; or a pharmaceutically acceptable salt thereof.
• R 7 and Rs together with the carbon atom to which they are both attached form a 4 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R7 and Rs is substituted with a group selected from amino, amino-methyl and methyl-amino; or a pharmaceutically acceptable salt thereof.
• compounds, or the pharmaceutically acceptable salt thereof selected from:
• Ri is selected from C6-ioaryl, C 3-8 cycloalkyl, C 3- scycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, 0 and S; wherein said aryl or heteroaryl of Ri a is substituted with 1 to 5 R 9 groups independently selected from halo, amino, hydroxy, N 3 , Ci- 4 alkyl, hydroxy-substituted-Ci- 4 alkyl, halo-substituted-Ci -4 alkyl, amino-substituted-Ci- alkyl, -C(O)ORi 0 and -NHC(O)Ri 0 ; wherein m is selected from 0, 1 and 2; each Ri 0a and Riob is independently selected from halo, amino, hydroxy, N 3 , Ci- 4 alkyl, hydroxy-substituted-Ci- 4 alkyl, halo-substituted-Ci
• n is selected from 1, 2, 3 and 4; p is selected from 0 and 1; q is selected from 0 and 1 ; Yi is selected from CH and N; Y 2 is selected from C 5 and N; Y 4 is selected from N and CRg; Re is selected from hydrogen, halo, methyl and amino-carbonyl; R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with a group selected from amino, amino-methyl and methyl- amino; Rg is selected from halo, amino, hydroxy, N 3 , Ci- 4 alkyl, halo-substituted-Ci- 4 alkyl, Ci_ 4 alkoxy, -C(O)ORi 0 and
• R 7 and Rs together with the carbon atom to which they are both attached form a 5 member saturated ring that can optionally contain a heteroatom selected from N, O and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with a group selected from amino, amino-methyl and methyl-amino; or a pharmaceutically acceptable salt thereof.
• R 7 and R 8 together with the carbon atom to which they are both attached form a 6 member saturated ring that can optionally contain a heteroatom selected from N, 0 and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with a group selected from amino, amino-methyl and methyl-amino; or a pharmaceutically acceptable salt thereof.
• R 7 and Rs together with the carbon atom to which they are both attached form a 4 member saturated ring that can optionally contain a heteroatom selected from N, O and S(0)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with amino; or a pharmaceutically acceptable salt thereof.
• the Src Homolgy-2 phosphatase (SHP2) is a protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3- kinase-AKT pathways. SHP2 mediates activation of Erkl and Erk2 (Erkl/2, Erk) MAP kinases by receptor tyrosine kinases such as ErbBl, ErbB2 and c-Met.
• SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail.
• the two SH2 domains control the subcellular localization and functional regulation of SHP2.
• the molecule exists in an inactive conformation, inhibiting its own activity via a binding network involving residues from both the N-SH2 and PTP domains.
• SHP2 binds to specific tyrosine- phosphorylated sites on docking proteins such as Gabl and Gab2 via its SH2 domains. This induces a conformational change that results in SHP2 activation.
• SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R).
• PDGF-R platelet-derived growth factor
• FGF-R fibroblast growth factor
• EGF-R epidermal growth factor
• SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer.
• MAP mitogen activated protein
• SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers.
• SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
• Noonan Syndrome (NS) and Leopard Syndrome (LS) - PTPN11 mutations cause LS (multiple lentigenes, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, sensorineural deafness) and NS (congenital anomalies including cardiac defects, craniofacial abnormalities and short stature). Both disorders are part of a family of autosomal dominant syndromes caused by germline mutations in components of the RAS/RAF MEK ERK mitogen activating protein kinase pathway, required for normal cell growth and differentiation.
• valvuloseptal defects and/or hypertrophic cardiomyopathy HCM
• Perturbations of the MAPK signaling pathway have been established as central to these disorders and several candidate genes along this pathway have been identified in humans, including mutations in KRAS, NRAS, SOS1, RAF1, BRAF, MEK1, MEK2, SHOC2, and CBL.
• the gene most commonly mutated in NS and LS is PTPN11.
• Germline mutations in PTPN11 (SHP2) are found in -50% of the cases with NS and nearly all patients with LS that shares certain features with NS.
• Y62D and Y63C substitutions in the protein are largely invariant and are among the most common mutations. Both these mutations affect the catalytically inactive conformation of SHP2 without perturbing the binding of the phosphatase to its phosphorylated signaling partners.
• JMML Juvenile Myelomonocytic Leukemias
• SHP2 myeloproliferative disorder
• Acute Myeloid Leukemia - PTPN11 mutations have been identified in:—10% of pediatric acute leukemias, such as myelodysplastic syndrome (MDS); -7% of B cell acute lymphoblastic leukemia (B-ALL); and -4% of acute myeloid leukemia (AML).
• MDS myelodysplastic syndrome
• B-ALL B cell acute lymphoblastic leukemia
• AML acute myeloid leukemia
• NS and leukemia mutations cause changes in amino acids located at the interface formed by the N-SH2 and PTP domains in the self -inhibited SHP2 conformation, disrupting the inhibitory intramolecular interaction, leading to hyperactivity of the catalytic domain.
• SHP2 acts as a positive regulator in receptor tyrosine kinase (RTK) signaling.
• Cancers containing RTK alterations include Esophageal, Breast, Lung, Colon, Gastric, Glioma, Head and Neck cancers.
• Esophageal cancer (or oesophageal cancer) is a malignancy of the esophagus.
• a SHP2 inhibitor of the invention can, therefore, be employed for innovative treatment strategies.
• Breast cancer is a major type of cancer and a leading cause of death in women, where patients develop resistance to current drugs.
• breast cancers There are four major subtypes of breast cancers including luminal A, luminal B, Her2 like, and triple negative/Basal-like.
• Triple negative breast cancer (TNBC) is an aggressive breast cancer lacking specific targeted therapy.
• Epidermal growth factor receptor I (EGFR) has emerged as a promising target in TNBC. Inhibition of Her2 as well as EGFR via SHP2 may be a promising therapy in breast cancer.
• Lung Cancer - NSCLC is currently a major cause of cancer-related mortality, accounting for about 85% of lung cancers ( predominantly adenocarcinomas and squamous cell carcinomas). Although cytotoxic chemotherapy remains an important part of treatment, targeted therapies based on genetic alterations such as EGFR and ALK in the tumor are more likely to benefit from a targeted therapy.
• Colon Cancer Approximately 30% to 50% of colorectal tumors are known to have a mutated (abnormal) KRAS, and BRAF mutations occur in 10 to 15% of colorectal cancers. For a subset of patients whose colorectal tumors have been demonstrated to over express EGFR, these patients exhibit a favorable clinical response to anti-EGFR therapy.
• Gastic Cancer is one of the most prevalent cancer types. Aberrant expression of tyrosine kinases, as reflected by the aberrant tyrosine phosphorylation in gastric cancer cells, is known in the art. Three receptor-tyrosine kinases, c-met (HGF receptor), FGF receptor 2, and erbB2/neu are frequently amplified in gastric carcinomas. Thus, subversion of different signal pathways may contribute to the progression of different types of gastric cancers.
• Neuroblastoma is a pediatric tumor of the developing sympathetic nervous system, accounting for about 8% of childhood cancers. Genomic alterations of the anaplastic lymphoma kinase (ALK) gene have been postulated to contribute to neuroblastoma pathogenesis.
• ALK anaplastic lymphoma kinase
• Squamous-cell carcinoma of the head and neck (SCCHN). High levels of
• EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking of the EGFR signaling results in inhibition of the stimulation of the receptor, cell proliferation, and reduced invasiveness and metastases.
• SCCHN head and neck
• the present invention relates to compounds capable of inhibiting the activity of
• the invention further provides a process for the preparation of compounds of the invention and pharmaceutical preparations comprising such compounds.
• Another aspect of the present invention relates to a method of treating SHP2 -mediated disorders comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of formula I as defined in the Summary of the Invention.
• the present invention relates to the aforementioned method, wherein said SHP2-mediated disorders are cancers selected from, but not limited to: JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; Gastric cancer, Head and Neck cancer.
• SHP2-mediated disorders are cancers selected from, but not limited to: JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; Gastric cancer, Head and Neck cancer.
• the compounds of the present invention may also be useful in the treatment of other diseases or conditions related to the aberrant activity of SHP2.
• the invention relates to a method of treatment of a disorder selected from: NS; LS; JMML; AML; MDS; B-ALL; neuroblastoma; esophageal; breast cancer; lung cancer; colon cancer; gastric cancer; head and neck cancer.
• a SHP2 inhibitor of the present invention may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of cancer.
• a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined above may be administered
• agents selected from chemotherapy agents for example, mitotic inhibitors such as a taxane, a vinca alkaloid, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine or vinflunine, and other anticancer agents, e.g. cisplatin, 5-fluorouracil or 5-fluoro-2-4(l H,3H)-pyrimidinedione (5FU), flutamide or gemcitabine.
• mitotic inhibitors such as a taxane, a vinca alkaloid, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine or vinflunine
• other anticancer agents e.g. cisplatin, 5-fluorouracil or 5-fluoro-2-4(l H,3H)-pyrimidinedione (5FU), flutamide or gemcitabine.
• Such combinations may offer significant advantages, including synergistic activity, in therapy.
• the present invention relates to the aforementioned method, wherein said compound is administered parenterally.
• the present invention relates to the aforementioned method, wherein said compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, intrathecally, topically or intranasally.
• the present invention relates to the aforementioned method, wherein said compound is administered systemically.
• the present invention relates to the aforementioned method, wherein said patient is a mammal.
• the present invention relates to the aforementioned method, wherein said patient is a primate.
• the present invention relates to the aforementioned method, wherein said patient is a human.
• the present invention relates to a method of treating an
• SHP2-mediated disorder comprising the step of: administering to a patient in need thereof a therapeutically effective amount of a chemothereutic agent in combination with a therapeutically effective amount of a compound of formula I as defined in the Summary of the Invention.
• the present invention provides pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
• the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained- release formulation; (3) topical application, for example, as a cream, ointment, or a controlled- release patch or spray applied to the skin; (4) intravaginally or intrarect
• terapéuticaally-effective amount means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
• phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• pharmaceutically-acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
• manufacturing aid e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid
• solvent encapsulating material involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
• Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
• materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydrox
• certain embodiments of the present compounds may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable acids.
• a basic functional group such as amino or alkylamino
• “pharmaceutically-acceptable salts” in this respect, refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed during subsequent purification.
• Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and
• the pharmaceutically acceptable salts of the subject compounds include the conventional nontoxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids.
• such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
• the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable bases.
• pharmaceutically-acceptable salts in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a
• Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
• Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. (See, for example, Berge et al., supra)
• wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
• antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha- tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
• water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
• oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
• Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
• the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
• the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
• the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.1 per cent to about ninety -nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 percent to about 30 percent.
• a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and poly anhydrides; and a compound of the present invention.
• an aforementioned formulation renders orally bioavailable a compound of the present invention.
• Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
• the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
• Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
• a compound of the present invention may also be administered as a bolus, electuary or paste.
• the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as
• compositions may also comprise buffering agents.
• Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
• a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
• Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface -active or dispersing agent.
• Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
• the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried.
• compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
• These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
• embedding compositions which can be used include polymeric substances and waxes.
• the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
• Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
• the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
• inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
• the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
• adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
• Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
• suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
• Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
• suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
• Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
• Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
• the active compound may be mixed under sterile conditions with a
• the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
• excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
• Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
• Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
• Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
• dosage forms can be made by dissolving or dispersing the compound in the proper medium.
• Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
• Ophthalmic formulations are also contemplated as being within the scope of this invention.
• compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
• aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
• polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
• vegetable oils such as olive oil
• injectable organic esters such as ethyl oleate.
• Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
• These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
• antibacterial and antifungal agents for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
• Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
• biodegradable polymers such as polylactide-polyglycolide.
• Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
• the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
• the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
• parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
• peripheral administration and “administered peripherally” as used herein mean the
• administration of a compound, drug or other material other than directly into the central nervous system such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
• These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
• the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
• Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
• the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
• a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
• a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, oral, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day.
• the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
• composition While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation (composition).
• the compounds according to the invention may be formulated for
• the present invention provides pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of one or more of the subject compounds, as described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
• compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin, lungs, or mucous membranes; or (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually or buccally; (6) ocularly; (7) transdermally; or (8) nasally.
• oral administration for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes for application to the tongue
• treatment is intended to encompass also prophylaxis, therapy and cure.
• the patient receiving this treatment is any animal in need, including primates, in particular humans, and other mammals such as equines, cattle, swine and sheep; and poultry and pets in general.
• the compound of the invention can be administered as such or in admixtures with pharmaceutically acceptable carriers and can also be administered in conjunction with antimicrobial agents such as penicillins, cephalosporins, aminoglycosides and glycopeptides.
• Conjunctive therapy thus includes sequential, simultaneous and separate administration of the active compound in a way that the therapeutical effects of the first administered one is not entirely disappeared when the subsequent is administered.
• Microemulsification technology can improve bioavailability of some lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic lipophilic
• microemulsification provides enhanced bioavailability by preferentially directing absorption to the lymphatic system instead of the circulatory system, which thereby bypasses the liver, and prevents destruction of the compounds in the hepatobiliary circulation.
• amphiphilic carriers While all suitable amphiphilic carriers are contemplated, the presently preferred carriers are generally those that have Generally-Recognized-as-Safe (GRAS) status, and that can both solubilize the compound of the present invention and microemulsify it at a later stage when the solution comes into a contact with a complex water phase (such as one found in human gastrointestinal tract).
• GRAS Generally-Recognized-as-Safe
• amphiphilic ingredients that satisfy these requirements have HLB (hydrophilic to lipophilic balance) values of 2-20, and their structures contain straight chain aliphatic radicals in the range of C-6 to C-20. Examples are polyethylene-glycolized fatty glycerides and polyethylene glycols.
• amphiphilic carriers are particularly contemplated, including Gelucire-series, Labrafil, Labrasol, or Lauroglycol (all manufactured and distributed by Gattefosse Corporation, Saint Priest, France), PEG-mono-oleate, PEG-di-oleate, PEG-mono- laurate and di-laurate, Lecithin, Polysorbate 80, etc (produced and distributed by a number of companies in USA and worldwide).
• Hydrophilic polymers suitable for use in the present invention are those which are readily water-soluble, can be covalently attached to a vesicle-forming lipid, and which are tolerated in vivo without toxic effects (i.e., are biocompatible).
• Suitable polymers include polyethylene glycol (PEG), polylactic (also termed polylactide), polyglycolic acid (also termed polyglycolide), a polylactic-polyglycolic acid copolymer, and polyvinyl alcohol.
• PEG polyethylene glycol
• polylactic also termed polylactide
• polyglycolic acid also termed polyglycolide
• a polylactic-polyglycolic acid copolymer a polyvinyl alcohol.
• Preferred polymers are those having a molecular weight of from about 100 or 120 daltons up to about 5,000 or 10,000 daltons, and more preferably from about 300 daltons to about 5,000 daltons.
• the polymer is polyethyleneglycol having a molecular weight of from about 100 to about 5,000 daltons, and more preferably having a molecular weight of from about 300 to about 5,000 daltons.
• the polymer is polyethyleneglycol of 750 daltons (PEG(750)).
• Polymers may also be defined by the number of monomers therein; a preferred embodiment of the present invention utilizes polymers of at least about three monomers, such PEG polymers consisting of three monomers (approximately 150 daltons).
• hydrophilic polymers which may be suitable for use in the present invention include polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline,
• polyhydroxypropyl methacrylamide polymethacrylamide, polydimethylacrylamide, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose.
• a formulation of the present invention comprises a biocompatible polymer selected from the group consisting of polyamides, polycarbonates, polyalkylenes, polymers of acrylic and methacrylic esters, polyvinyl polymers, polyglycolides, polysiloxanes, polyurethanes and co-polymers thereof, celluloses, polypropylene, polyethylenes, polystyrene, polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, poly(butic acid), poly(valeric acid), poly(lactide-co-caprolactone), polysaccharides, proteins, polyhyaluronic acids, polycyanoacrylates, and blends, mixtures, or copolymers thereof.
• a biocompatible polymer selected from the group consisting of polyamides, polycarbonates, polyalkylenes, polymers of acrylic and methacrylic esters, polyvinyl polymers, polyglycolides, polysiloxanes, polyurethanes and
• Cyclodextrins are cyclic oligosaccharides, consisting of 6, 7 or 8 glucose units, designated by the Greek letter alpha, beta or gamma, respectively. Cyclodextrins with fewer than six glucose units are not known to exist. The glucose units are linked by alpha- 1,4-glucosidic bonds. As a consequence of the chair conformation of the sugar units, all secondary hydroxyl groups (at C-2, C-3) are located on one side of the ring, while all the primary hydroxyl groups at C-6 are situated on the other side. As a result, the external faces are hydrophilic, making the cyclodextrins water-soluble.
• the cavities of the cyclodextrins are hydrophobic, since they are lined by the hydrogen of atoms C-3 and C-5, and by ether-like oxygens.
• These matrices allow complexation with a variety of relatively hydrophobic compounds, including, for instance, steroid compounds such as 17.beta. -estradiol (see, e.g., van Uden et al. Plant Cell Tiss. Org. Cult. 38: 1-3-113 (1994)).
• the complexation takes place by Van der Waals interactions and by hydrogen bond formation.
• the physico-chemical properties of the cyclodextrin derivatives depend strongly on the kind and the degree of substitution. For example, their solubility in water ranges from insoluble (e.g., triacetyl-beta-cyclodextrin) to 147% soluble (w/v) (G-2-beta-cyclodextrin). In addition, they are soluble in many organic solvents. The properties of the cyclodextrins enable the control over solubility of various formulation components by increasing or decreasing their solubility.
• Liposomes consist of at least one lipid bilayer membrane enclosing an aqueous internal compartment. Liposomes may be characterized by membrane type and by size. Small unilamellar vesicles (SUVs) have a single membrane and typically range between 0.02 and 0.05 ⁇ in diameter; large unilamellar vesicles (LUVS) are typically larger than 0.05 ⁇
• Oligolamellar large vesicles and multilamellar vesicles have multiple, usually concentric, membrane layers and are typically larger than 0.1 ⁇ . Liposomes with several nonconcentric membranes, i.e., several smaller vesicles contained within a larger vesicle, are termed multivesicular vesicles.
• One aspect of the present invention relates to formulations comprising liposomes containing a compound of the present invention, where the liposome membrane is formulated to provide a liposome with increased carrying capacity.
• the compound of the present invention may be contained within, or adsorbed onto, the liposome bilayer of the liposome.
• the compound of the present invention may be aggregated with a lipid surfactant and carried within the liposome's internal space; in these cases, the liposome membrane is formulated to resist the disruptive effects of the active agent-surfactant aggregate.
• the lipid bilayer of a liposome contains lipids derivatized with polyethylene glycol (PEG), such that the PEG chains extend from the inner surface of the lipid bilayer into the interior space encapsulated by the liposome, and extend from the exterior of the lipid bilayer into the surrounding environment.
• PEG polyethylene glycol
• Active agents contained within liposomes of the present invention are in solubilized form. Aggregates of surfactant and active agent (such as emulsions or micelles containing the active agent of interest) may be entrapped within the interior space of liposomes according to the present invention.
• a surfactant acts to disperse and solubilize the active agent, and may be selected from any suitable aliphatic, cycloaliphatic or aromatic surfactant, including but not limited to biocompatible lysophosphatidylcholines (LPCs) of varying chain lengths (for example, from about C. sub.14 to about C.sub.20).
• Polymer-derivatized lipids such as PEG-lipids may also be utilized for micelle formation as they will act to inhibit micelle/membrane fusion, and as the addition of a polymer to surfactant molecules decreases the CMC of the surfactant and aids in micelle formation.
• Liposomes according to the present invention may be prepared by any of a variety of techniques that are known in the art. See, e.g., U.S. Pat. No. 4,235,871; Published PCT applications WO 96/14057; New RRC, Liposomes: A practical approach, IRL Press, Oxford (1990), pages 33-104; Lasic DD, Liposomes from physics to applications, Elsevier Science Publishers BV, Amsterdam, 1993.
• liposomes of the present invention may be prepared by diffusing a lipid derivatized with a hydrophilic polymer into preformed liposomes, such as by exposing preformed liposomes to micelles composed of lipid-grafted polymers, at lipid concentrations corresponding to the final mole percent of derivatized lipid which is desired in the liposome.
• Liposomes containing a hydrophilic polymer can also be formed by homogenization, lipid-field hydration, or extrusion techniques, as are known in the art.
• the liposomes are prepared to have substantially homogeneous sizes in a selected size range.
• One effective sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size; the pore size of the membrane will correspond roughly with the largest sizes of liposomes produced by extrusion through that membrane. See e.g., U.S. Pat. No. 4,737,323 (Apr. 12, 1988).
• the release characteristics of a formulation of the present invention depend on the encapsulating material, the concentration of encapsulated drug, and the presence of release modifiers.
• release can be manipulated to be pH dependent, for example, using a pH sensitive coating that releases only at a low pH, as in the stomach, or a higher pH, as in the intestine.
• An enteric coating can be used to prevent release from occurring until after passage through the stomach.
• Multiple coatings or mixtures of cyanamide encapsulated in different materials can be used to obtain an initial release in the stomach, followed by later release in the intestine.
• Release can also be manipulated by inclusion of salts or pore forming agents, which can increase water uptake or release of drug by diffusion from the capsule.
• Excipients which modify the solubility of the drug can also be used to control the release rate.
• Agents which enhance degradation of the matrix or release from the matrix can also be incorporated. They can be added to the drug, added as a separate phase (i.e., as particulates), or can be co-dissolved in the polymer phase depending on the compound. In all cases the amount should be between 0.1 and thirty percent (w/w polymer).
• Types of degradation enhancers include inorganic salts such as ammonium sulfate and ammonium chloride, organic acids such as citric acid, benzoic acid, and ascorbic acid, inorganic bases such as sodium carbonate, potassium carbonate, calcium carbonate, zinc carbonate, and zinc hydroxide, and organic bases such as protamine sulfate, spermine, choline, ethanolamine, diethanolamine, and triethanolamine and surfactants such as Tween® and Pluronic®.
• Pore forming agents which add microstructure to the matrices i.e., water soluble compounds such as inorganic salts and sugars
• the range should be between one and thirty percent (w/w polymer).
• Uptake can also be manipulated by altering residence time of the particles in the gut. This can be achieved, for example, by coating the particle with, or selecting as the encapsulating material, a mucosal adhesive polymer.
• a mucosal adhesive polymer examples include most polymers with free carboxyl groups, such as chitosan, celluloses, and especially polyacrylates (as used herein, polyacrylates refers to polymers including acrylate groups and modified acrylate groups such as cyanoacrylates and methacrylates).
• the invention especially relates to the use of a compound of the formula I (or a pharmaceutical composition comprising a compound of the formula I) in the treatment of one or more of the diseases mentioned herein; wherein the response to treatment is beneficial as demonstrated, for example, by the partial or complete removal of one or more of the symptoms of the disease up to complete cure or remission.
• a compound of formula (I) can also be used in combination with the following compounds and antibody-drug conjugates:
• BCR-ABL inhibitors Imatinib (Gleevec®); Inilotinib hydrochloride; Nilotinib (Tasigna®); Dasatinib (BMS-345825); Bosutinib (SKI-606); Ponatinib (AP24534); Bafetinib (IN O406); Danusertib (PHA-739358), AT9283 (CAS 1133385-83-7); Saracatinib (AZD0530); and N-[2-[(lS,4R)-6-[[4-(Cyclobutylamino)-5-(tjifluoromethyl)-2-pyrimidinyl]amino]-l,2,3,4- tetrahydronaphthalen-l,4-imin-9-yl]-2-oxoethyl]-acetamide (PF-03814735, CAS 942487-16-3); and LGX818.
• ALK inhibitors PF-2341066 (XALKORI ® ; crizotinib); 5-chloro-N4-(2-
• BRAF inhibitors Vemurafanib (PLX4032); and Dabrafenib.
• FLT3 inhibitors - sunitinib malate sold under the tradename Sutent® by Pfizer
• PKC412 midostaurin
• tanutinib sorafenib
• sunitinib midostaurin
• lestaurtinib KW-2449
• quizartinib AC220
• crenolanib crenolanib
• VEGF receptor inhibitors Bevacizumab (sold under the trademark Avastin® by Genentech/Roche), axitinib, (N-methyl-2-[[3-[(E)-2-pyridin-2- ylethenyl]-lH-indazol-6-yl]sulfanyl]benzamide, also known as AGO 13736, and described in PCT Publication No.
• HER2 receptor inhibitors Trastuzumab (sold under the trademark Herceptin® by Genentech/Roche), neratinib (also known as HKI-272, (2E)-N-[4-[[3-chloro-4-[(pyridin-2- yl)methoxy]phenyl] amino] -3 -cy ano-7-ethoxyquinolin-6-yl] -4-(dimethylamino)but-2-enamide, and described PCT Publication No.
• lapatinib or lapatinib ditosylate sold under the trademark Tykerb® by Glaxo SmithKline
• Trastuzumab emtansine in the United States, ado- trastuzumab emtansine, trade name Kadcyla
• an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1);
• CD20 antibodies Rituximab (sold under the trademarks Riuxan® and MabThera® by Genentech/Roche), tositumomab (sold under the trademarks Bexxar® by GlaxoSmithKline), ofatumumab (sold under the trademark Arzerra® by GlaxoSmithKline);
• Tyrosine kinase inhibitors Erlotinib hydrochloride (sold under the trademark Tarceva® by Genentech Roche), Linifanib (N-[4-(3-amino-lH-indazol-4-yl)phenyl]-N'-(2-fluoro-5- methylphenyl)urea, also known as ABT 869, available from Genentech), sunitinib malate (sold under the tradename Sutent® by Pfizer), bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6- methoxy
• dasatinib (sold under the tradename Sprycel® by Bristol-Myers Squibb), armala (also known as pazopanib, sold under the tradename Votrient® by GlaxoSmithKline), imatinib and imatinib mesylate (sold under the tradenames Gilvec® and Gleevec® by Novartis);
• DNA Synthesis inhibitors Capecitabine (sold under the trademark Xeloda® by Roche), gemcitabine hydrochloride (sold under the trademark Gemzar® by Eli Lilly and Company), nelarabine ((2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4- diol, sold under the tradenames Arranon® and Atriance® by GlaxoSmithKline);
• Antineoplastic agents oxaliplatin (sold under the tradename Eloxatin® ay Sanofi- Aventis and described in US Patent No. 4,169,846);
• Epidermal growth factor receptor (EGFR) inhibitors Gefitnib (sold under the tradename Iressa®), N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3"S")-tetrahydro-3-furanyl]oxy]-6- quinazolinyl]-4(dimethylamino)-2-butenamide, sold under the tradename Tovok® by Boehringer Ingelheim), cetuximab (sold under the tradename Erbitux® by Bristol-Myers Squibb), panitumumab (sold under the tradename Vectibix® by Amgen);
• HER dimerization inhibitors Pertuzumab (sold under the trademark Omnitarg®, by Genentech);
• G-CSF modulators Filgrastim (sold under the tradename Neupogen® by Amgen);
• Immunomodulators Afutuzumab (available from Roche®), pegfilgrastim (sold under the tradename Neulasta® by Amgen), lenalidomide (also known as CC-5013, sold under the tradename Revlimid®), thalidomide (sold under the tradename Thalomid®);
• CD40 inhibitors Dacetuzumab (also known as SGN-40 or huS2C6, available from Seattle Genetics, Inc);
• PARAs Pro-apoptotic receptor agonists
• Dulanermin also known as AMG-951, available from Amgen/Genentech;
• Hedgehog antagonists 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)- benzamide (also known as GDC-0449, and described in PCT Publication No. WO 06/028958);
• PI3K inhibitors 4-[2-(lH-Indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-l- yl]methyl]thieno[3,2-d]pyrimidin-4-yl]mo holine (also known as GDC 0941 and described in PCT Publication Nos.
• Phospholipase A2 inhibitors Anagrelide (sold under the tradename Agrylin®);
• BCL-2 inhibitors 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohexen-l-yl]methyl]-l- piperazinyl] -N- [ [4- [ [( 1 R)-3 -(4-morpholinyl)- 1 - [(phenylthio)methyl]propyl] amino] -3 - [(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (also known as ABT-263 and described in PCT Publication No. WO 09/155386);
• Mitogen-activated protein kinase kinase (MEK) inhibitors XL-518 (Cas No. 1029872- 29-4, available from ACC Corp.);
• Aromatase inhibitors Exemestane (sold under the trademark Aromasin® by Pfizer), letrozole (sold under the tradename Femara® by Novartis), anastrozole (sold under the tradename Arimidex®);
• Topoisomerase I inhibitors Irinotecan (sold under the trademark Camptosar® by Pfizer), topotecan hydrochloride (sold under the tradename Hycamtin® by Glaxo SmithKline);
• Topoisomerase II inhibitors also known as VP- 16 and Etoposide phosphate, sold under the tradenames Toposar®, VePesid® and Etopophos®), teniposide (also known as VM-26, sold under the tradename Vumon®);
• mTOR inhibitors Temsirolimus (sold under the tradename Torisel® by Pfizer), ridaforolimus (formally known as deferolimus, (lR,2R,4S)-4-[(2R)-2
• Osteoclastic bone resorption inhibitors l-Hydroxy-2-imidazol-l-yl-phosphonoethyl) phosphonic acid monohydrate (sold under the tradename Zometa® by Novartis);
• CD33 Antibody Drug Conjugates Gemtuzumab ozogamicin (sold under the tradename
• CD22 Antibody Drug Conjugates Inotuzumab ozogamicin (also referred to as CMC-
• CD20 Antibody Drug Conjugates Ibritumomab tiuxetan (sold under the tradename
• octreotide also known as octreotide acetate, sold under the tradenames Sandostatin® and Sandostatin LAR®
• Sandostatin® also known as octreotide acetate, sold under the tradenames Sandostatin® and Sandostatin LAR®
• Synthetic Interleukin-11 (IL-11): oprelvekin (sold under the tradename Neumega® by Pfizer/Wyeth);
• Receptor Activator for Nuclear Factor ⁇ B (RANK) inhibitors Denosumab (sold under the tradename Prolia® by Amgen);
• Thrombopoietin mimetic peptibodies Romiplostim (sold under the tradename Nplate® by Amgen;
• Cell growth stimulators Palifermin (sold under the tradename Kepivance® by Amgen);
• IGF-1R Anti-Insulin-like Growth Factor- 1 receptor antibodies: Figitumumab (also known as CP-751,871, available from ACC Corp), robatumumab (CAS No. 934235-44-6);
• Anti-CSl antibodies Elotuzumab (HuLuc63, CAS No. 915296-00-3);
• CD52 antibodies Alemtuzumab (sold under the tradename Campath®);
• CTLA-4 inhibitors Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206), ipilimumab (CTLA-4 antibody, also known as MDX-010, CAS No. 477202-00-9);
• PD1 inhibitors Nivolumab (also referred to herein as MDX-1106, MDX-1106-04, ONO-4538, BMS0936558, CAS Registry No: 946414-94-4) disclosed in, for example, US 8,008,449, and having a sequence disclosed therein (or a sequence substantially identical or similar thereto, for example, a sequence having at least 85%, 90%, 95% identity or greater to the sequence specified in US 8,008,449); Pembrolizumab (also referred to herein as Lambrolizumab, MK-3475, MK03475, SCH-900475 or KEYTRUDA), disclosed in, for example, US 8,354,509 and WO 2009/114335, and having a sequence disclosed therein (or a sequence substantially identical or similar thereto, for example, a sequence having at least 85%, 90%, 95% identity or greater to the sequence specified in US 8,354,509 and WO2009/114335); an immunoadhesin (for example
• PDL1 inhibitors MSB0010718C (also referred to as A09-246-2; Merck Serono) is a monoclonal antibody that binds to PD-Ll and is disclosed in, for example, WO 2013/0179174, (and having a sequence substantially identical or similar thereto, for example, a sequence having at least 85%, 90%, 95% identity or higher to the sequence specified in WO 2013/0179174); and anti-PD-Ll binding antagonist selected from YW243.55.S70, MPDL3280A (Genetech/Roche) is a human Fc optimized IgGl monoclonal antibody that binds to PD-Ll (MDPL3280A and other human monoclonal antibodies to PD-Ll are disclosed in U.S.
• BMS-986016 (also referred to as BMS986016; Bristol-Myers Squibb) is a monoclonal antibody that binds to LAG-3.
• BMS-986016 and other humanized anti-LAG-3 antibodies are disclosed in US 2011/0150892, WO2010/019570, and WO2014/008218.
• GITR agonists include, for example., GITR fusion proteins and anti-GITR antibodies (for example, bivalent anti-GITR antibodies), such as, a GITR fusion protein described in U.S. Patent No.: 6,111,090, European Patent No.: 090505B1, U.S Patent No.: 8,586,023, PCT Publication Nos.: WO 2010/003118 and 2011/090754, or an anti-GITR antibody described, /or example, in U.S. Patent No.: 7,025,962, European Patent No.: 1947183B1, U.S. Patent No.: 7,812,135, U.S. Patent No.: 8,388,967, U.S. Patent No.: 8,591,886, European Patent No.: EP 1866339, PCT Publication No. : WO 2011/028683, PCT Publication No.: WO
• Histone deacetylase inhibitors (HDI): Voninostat (sold under the tradename Zolinza® by Merck).
• anti-CTLA4 antibodies include Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206); and Ipilimumab (CTLA-4 antibody, also known as MDX-010, CAS No. 477202-00-9).
• Tremelimumab IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206
• Ipilimumab CLA-4 antibody, also known as MDX-010, CAS No. 477202-00-9
• Alkylating agents Temozolomide (sold under the tradenames Temodar® and
• Temodal® by Schering-Plough/Merck dactinomycin (also known as actinomycin-D and sold under the tradename Cosmegen®), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename Alkeran®), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename Hexalen®), carmustine (sold under the tradename BiCNU®), bendamustine (sold under the tradename Treanda®), busulfan (sold under the tradenames Busulfex® and Myleran®), carboplatin (sold under the tradename Paraplatin®), lomustine (also known as CCNU, sold under the tradename CeeNU®), cisplatin (also known as CDDP, sold under the tradenames Platinol® and Platinol®-AQ), chlorambucil (sold under the tradename Leukeran®), cycl
• Biologic response modifiers bacillus calmette-guerin (sold under the tradenames theraCys® and TICE® BCG), denileukin diftitox (sold under the tradename Ontak®);
• Anti-tumor antibiotics doxorubicin (sold under the tradenames Adriamycin® and Rubex®), bleomycin (sold under the tradename lenoxane®), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename Cerubidine®), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome®), mitoxantrone (also known as DHAD, sold under the tradename Novantrone®), epirubicin (sold under the tradename EllenceTM), idarubicin (sold under the tradenames Idamycin®, Idamycin PFS®), mitomycin C (sold under the tradename Mutamycin®);
• Anti-microtubule agents Estramustine (sold under the tradename Emcyl®);
• Cathepsin K inhibitors Odanacatib (also know as MK-0822, N-(l-cyanocyclopropyl)- 4-fluoro-N 2 - ⁇ ( 1 S)-2,2,2-trifluoro- 1 - [4'-(methylsulfonyl)biphenyl-4-yl]ethyl ⁇ -L-leucinamide, available from Lanzhou Chon Chemicals, ACC Corp., and ChemieTek, and described in PCT Publication no. WO 03/075836);
• Epothilone B analogs Ixabepilone (sold under the tradename Lxempra® by Bristol- Myers Squibb);
• HSP Heat Shock Protein
• TpoR agonists Eltrombopag (sold under the tradenames Promacta® and Revolade® by Glaxo SmithKline) ;
• Anti-mitotic agents Docetaxel (sold under the tradename Taxotere® by Sanofi- Aventis);
• Adrenal steroid inhibitors aminoglutethimide (sold under the tradename Cytadren®);
• Anti-androgens Nilutamide (sold under the tradenames Nilandron® and Anandron®), bicalutamide (sold under tradename Casodex®), flutamide (sold under the tradename FulexinTM);
• Androgens Fluoxymesterone (sold under the tradename Halotestin®);
• Proteasome inhibitors Bortezomib (sold under the tradename Velcade®);
• CDK1 inhibitors Alvocidib (also known as flovopirdol or HMR-1275, 2-(2- chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-l-methyl-4-piperidinyl]-4-chromenone, and described in US Patent No. 5,621,002);
• GnRH Gonadotropin -releasing hormone receptor agonists: Leuprolide or leuprolide acetate (sold under the tradenames Viadure® by Bayer AG, Eligard® by Sanofi-Aventis and Lupron® by Abbott Lab);
• Taxane anti-neoplastic agents Cabazitaxel (1 -hydroxy ⁇ , 10 -dimethoxy-9-oxo-5 ,20- epoxytax-1 l-ene-2a,4,13a-triyl-4-acetate-2-benzoate-13-[(2R,3S)-3- ⁇ [(tert- butoxy)carbonyl]amino ⁇ -2-hydroxy-3-phenylpropanoate), larotaxel ((2 ⁇ ,3 ⁇ ,4 ⁇ ,5 ⁇ ,7 ⁇ ,10 ⁇ ,13 ⁇ )- 4,10-bis(acetyloxy)-13-( ⁇ (2R,3S)-3- [(tert-butoxycarbonyl) amino]-2-hydroxy-3- phenylpropanoyl ⁇ oxy)-l- hydroxy-9-oxo-5,20-epoxy-7,19-cyclotax-l l-en-2-yl benzoate);
• 5HTla receptor agonists Xaliproden (also known as SR57746, l-[2-(2-naphthyl)ethyl]- 4-[3-(trifluoromethyl)phenyl]-l,2,3,6-tetrahydropyridine, and described in US Patent No.
• HPC vaccines Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck;
• Iron Chelating agents Deferasinox (sold under the tradename Exjade® by Novartis);
• Anti-metabolites Claribine (2-chlorodeoxyadenosine, sold under the tradename leustatin®), 5-fluorouracil (sold under the tradename Adrucil®), 6-thioguanine (sold under the tradename Purinethol®), pemetrexed (sold under the tradename Alimta®), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename Cytosar-U®), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCytTM), decitabine (sold under the tradename Dacogen®), hydroxyurea (sold under the tradenames Hydrea®, DroxiaTM and MylocelTM), fludarabine (sold under the tradename Fludara®), floxuridine (sold under the tradename FUDR®), cladribine (also known as 2-chlorode
• Bisphosphonates Pamidronate (sold under the tradename Aredia®), zoledronic acid (sold under the tradename Zometa®); [00215] Demethylating agents: 5-azacitidine (sold under the tradename Vidaza®), decitabine (sold under the tradename Dacogen®);
• Plant Alkaloids Paclitaxel protein-bound (sold under the tradename Abraxane®), vinblastine (also known as vinblastine sulfate, vincaleukoblastine and VLB, sold under the tradenames Alkaban-AQ® and Velban®), vincristine (also known as vincristine sulfate, LCR, and VCR, sold under the tradenames Oncovin® and Vincasar Pfs®), vinorelbine (sold under the tradename Navelbine®), paclitaxel (sold under the tradenames Taxol and OnxalTM);
• Retinoids Alitretinoin (sold under the tradename Panretin®), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the tradename Vesanoid®), Isotretinoin (13-cis-retinoic acid, sold under the tradenames Accutane®, Amnesteem®, Claravis®, Claras®, Decutan®, Isotane®, Izotech®, Oratane®, Isotret®, and Sotret®), bexarotene (sold under the tradename Targretin®);
• Glucocorticosteroids Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and sold under the tradenames Ala-Cort®, Hydrocortisone Phosphate, Solu-Cortef®, Hydrocort Acetate® and Lanacort®), dexamethazone ((8S,9R,10S,l lS,13S,14S,16R,17R)-9-fluoro-l l,17-dihydroxy-17-(2 -hydroxy acetyl)-10,13,16- trimethyl-6,7,8,9,10,11,12, 13, 14,15, 16, 17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one), prednisolone (sold under the tradenames Delta-Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (sold under the tradenames Delta-Cor
• Cytokines interleukin-2 (also known as aldesleukin and IL-2, sold under the tradename Proleukin®), interleukin-11 (also known as oprevelkin, sold under the tradename Neumega®), alpha interferon alfa (also known as IFN-alpha, sold under the tradenames Intron® A, and Roferon-A®);
• Estrogen receptor downregulators Fulvestrant (sold under the tradename Faslodex®);
• Anti-estrogens tamoxifen (sold under the tradename Novaldex®);
• Toremifene (sold under the tradename Fareston®); [00223] Selective estrogen receptor modulators (SERMs): Raloxifene (sold under the tradename Evista®);
• LHRH Leutinizing hormone releasing hormone
• megestrol also known as megestrol acetate, sold under the tradename Megace®
• Trisenox® asparaginase (also known as L-asparaginase, Erwinia L-asparaginase, sold under the tradenames Elspar® and Kidrolase®);
• a compound of formula (I) can also be used in combination with the following adjunct therapies:
• Anti-nausea drugs NK-1 receptor antagonists: Casopitant (sold under the tradenames Rezonic® and Zunrisa® by GlaxoSmithKline); and
• Cytoprotective agents Amifostine (sold under the tradename Ethyol®), leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid).
• Immune checkpoint inhibitors include an inhibitor of an inhibitory molecule of an immune checkpoint molecule.
• the term “immune checkpoints” refers to a group of molecules on the cell surface of CD4 and CD8 T cells. These molecules can effectively serve as “brakes” to down-modulate or inhibit an antitumor immune response.
• Immune checkpoint molecules include, but are not limited to, Programmed Death 1 (PD-1), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), B7H1, B7H4, OX- 40, CD 137, CD40, and LAG3, which directly inhibit immune cells
• immunotherapeutic agents which can act as immune checkpoint inhibitors useful in the methods of the present invention, include, but are not limited to, inhibitors of PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD 160, 2B4 and/or TGFR beta. Inhibition of an inhibitory molecule can be performed by inhibition at the DNA, RNA or protein level.
• an inhibitory nucleic acid e.g., a dsRNA, siRNA or shRNA
• the inhibitor of an inhibitory signal is, a polypeptide e.g., a soluble ligand, or an antibody or antigen-binding fragment thereof, that binds to the inhibitory molecule.
• the anti-PD- 1 molecules described herein are administered in combination with one or more other inhibitors of PD-1, PD-L1 and/or PD-L2 known in the art.
• the antagonist may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
• the combination therapies disclosed herein include a modulator of a costimulatory molecule or an inhibitory molecule, e.g., a co-inhibitory ligand or receptor.
• the costimulatory modulator, e.g., agonist, of a costimulatory molecule is chosen from an agonist (e.g., an agonistic antibody or antigen-binding fragment thereof, or soluble fusion) of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CDl la/CD18), ICOS (CD278), 4- IBB (CD 137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand.
• an agonist e.g., an agonistic antibody or antigen-binding fragment thereof, or soluble fusion
• OX40 e.g., CD2, CD27, CDS, ICAM-1, LFA-1 (CDl la/CD18), ICOS (CD278), 4- IBB (CD 137), GITR, CD30, CD40, BAFFR, HVEM,
• the combination therapies disclosed herein include a costimulatory molecule, e.g., an agonist associated with a positive signal that includes a costimulatory domain of CD28, CD27, ICOS and GITR.
• a costimulatory molecule e.g., an agonist associated with a positive signal that includes a costimulatory domain of CD28, CD27, ICOS and GITR.
• the anti-PD- 1 antibody molecule is administered after treatment, e.g., after treatment of a melanoma, with an anti-CTLA4 antibody (e.g., ipilimumab) with or without a BRAF inhibitor (e.g., vemurafenib or dabrafenib).
• an anti-CTLA4 antibody e.g., ipilimumab
• BRAF inhibitor e.g., vemurafenib or dabrafenib
• exemplary doses that can be use include a dose of anti-PD-1 antibody molecule of about 1 to 10 mg/kg, e.g., 3 mg/kg, and a dose of an anti-CTLA-4 antibody, e.g., ipilimumab, of about 3 mg/kg.
• the anti-PD-1 or PD-L1 antibody molecule is administered in combination with an anti-LAG-3 antibody or an antigen-binding fragment thereof.
• the anti-PD-1 or PD-L1 antibody molecule is administered in combination with an anti-TIM-3 antibody or antigen-binding fragment thereof.
• the anti-PD- 1 or PD-L1 antibody molecule is administered in combination with an anti-LAG-3 antibody and an anti-TIM-3 antibody, or antigen-binding fragments thereof.
• the combination of antibodies recited herein can be administered separately, e.g., as separate antibodies, or linked, e.g., as a bispecific or trispecific antibody molecule.
• a bispecific antibody that includes an anti-PD-1 or PD-L1 antibody molecule and an anti-TIM-3 or anti-LAG-3 antibody, or antigen-binding fragment thereof, is administered.
• the combination of antibodies recited herein is used to treat a cancer, e.g., a cancer as described herein (e.g., a solid tumor).
• a cancer e.g., a cancer as described herein (e.g., a solid tumor).
• the efficacy of the aforesaid combinations can be tested in animal models known in the art. For example, the animal models to test the synergistic effect of anti-PD-1 and anti-LAG-3 are described, e.g., in Woo et al. (2012) Cancer Res. 72(4):917-27).
• the combination therapy disclosed herein ⁇ e.g., an anti-PD-1 or PD-Ll antibody molecule, alone or in combination with another immunomodulator ⁇ e.g., an anti- LAG-3, or anti-TIM-3 antibody molecule).
• the anti-PD-1 or PD-Ll antibody molecule is administered in combination with an anti-LAG-3 antibody or an antigen-binding fragment thereof.
• the anti-PD-1 or PD-Ll antibody molecule is administered in combination with an anti-TIM-3 antibody or antigen-binding fragment thereof.
• the anti-PD-1 or PD-Ll antibody molecule is administered in combination with an anti-LAG-3 antibody and an anti-TIM-3 antibody, or antigen-binding fragments thereof.
• the combination of antibodies recited herein can be administered separately, e.g., as separate antibodies, or linked, e.g., as a bispecific or trispecific antibody molecule.
• a bispecific antibody that includes an anti-PD-1 or PD-Ll antibody molecule and an anti-TIM-3 or anti-LAG-3 antibody, or antigen-binding fragment thereof, is administered.
• the combination of antibodies recited herein is used to treat a cancer, e.g., a cancer as described herein ⁇ e.g., a solid tumor).
• a cancer e.g., a cancer as described herein ⁇ e.g., a solid tumor.
• the efficacy of the aforesaid combinations can be tested in animal models known in the art. For example, the animal models to test the synergistic effect of anti-PD-1 and anti-LAG-3 are described, e.g., in Woo et al. (2012) Cancer Res.
• the antibody molecule is in the form of a bispecific or multispecific antibody molecule.
• the bispecific antibody molecule has a first binding specificity to PD-1 or PD-Ll and a second binding specifity, e.g., a second binding specificity to TIM-3, LAG-3, or PD-L2.
• the bispecific antibody molecule binds to PD-1 or PD-Ll and TIM-3.
• the bispecific antibody molecule binds to PD-1 or PD-Ll and LAG-3.
• the bispecific antibody molecule binds to PD-1 or PD-Ll.
• the bispecific antibody molecule binds to PD-1 and PD-L2. In another embodiment, the bispecific antibody molecule binds to TIM-3 and LAG-3. Any combination of the aforesaid molecules can be made in a multispecific antibody molecule, e.g., a trispecific antibody that includes a first binding specificity to PD-1 or PD-1, and a second and third binding specifities to two or more of: TIM-3, LAG-3, or PD-L2.
• the present invention also includes processes for the preparation of compounds of the invention.
• reactive functional groups for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
• Conventional protecting groups can be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991.
• Q is a halogen (like bromine) or a thiol, boronate or stannate which reacts with a halogen on compound 5
• X is a reactive group which reacts with Q (such as a boronate, stannane, alcohol, thiol, halogen, and the like).
• Compound 4 may be prepared by reacting compound 2 with compound 3 through a reaction under suitable acid or base conditions in the presence or absence of a transition metal under ambient temperature, or under thermal or microwave conditions.
• the halogen of compound 2 may be replaced by other halogens or suitable activating groups such as triflates, mesylates, tosylates, nonaflates, boronates, organostannanes, organosilyls, organozincs, lithium, magnesium, and the like.
• a compound of formula I can be prepared by reacting compound 4 with a suitable coupling partner (e.g. compound 5) depending on X.
• a suitable coupling partner e.g. compound 5
• compound 5 is shown in reaction scheme I as a substituted phenyl group linked via X.
• compound 5 could be aryl-alcohol, aryl-thio, aryl-boronate, aryl-stannate, heteroaryl-alcohol, aryl-thiol, heteroaryl- thiol, aryl-boronate, aryl-stannane, olefin, or other aryl-metals or heteroaryl-metals, and the like.
• the coupling partners may also be substituted.
• This reaction may be conducted under suitable acid or base conditions, in the presence or absence of a transition metal such as palladium, under ambient temperature, or under thermal or microwave conditions.
• a transition metal such as palladium
• Other halogens or suitable activating groups e.g., triflates, mesylates, tosylates, and nonaflates
• triflates, mesylates, tosylates, and nonaflates may be used in place of Br for these transformations.
• compound 2 may be derivatized to a stannane, boronate, organo-zinc, organo-lithium, organo-magnesium, organo- silicon, organo-cuprate and coupled with a suitable aryl-halide, heteroaryl-halide, olefin or suitable reactive functional group (e.g., triflates, mesylates, tosylates and nonaflates), and the like.
• a suitable aryl-halide, heteroaryl-halide, olefin or suitable reactive functional group e.g., triflates, mesylates, tosylates and nonaflates
• a compound of the invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
• a pharmaceutically acceptable base addition salt of a compound of the invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
• Compounds of the formula I can also be modified by appending appropriate functionalities to enhance selective biological properties. Modifications of this kind are known in the art and include those that increase penetration into a given biological system (e.g. blood, lymphatic system, central nervous system, testis), increase bioavailability, increase solubility to allow parenteral administration (e.g.
• estersification e.g. with polyethylene glycols, derivatisation with pivaloyloxy or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings and heteroatom substitution in aromatic rings.
• the salt forms of the compounds of the invention can be prepared using salts of the starting materials or intermediates.
• any reference to the compounds or a compound of the formula I hereinbefore and hereinafter is to be understood as referring to the compound in free form and/or also to one or more salts thereof, as appropriate and expedient, as well as to one or more solvates, e.g. hydrates.
• Salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula I with a basic nitrogen atom, especially the pharmaceutically acceptable salts.
• Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
• Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, malonic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-
• the free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively.
• a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
• a suitable base e.g., ammonium hydroxide solution, sodium hydroxide, and the like.
• a compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).
• Compounds of the invention in unoxidized form can be prepared from N- oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.
• a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
• a suitable inert organic solvent e.g. acetonitrile, ethanol, aqueous dioxane, or the like
• Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
• appropriate prodrugs can be prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate, or the like).
• Protected derivatives of the compounds of the invention can be made by means known to those of ordinary skill in the art. A detailed description of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, "Protecting Groups in Organic Chemistry", 3 rd edition, John Wiley and Sons, Inc., 1999.
• Compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
• Compounds of the invention can be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of the compounds of the invention, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
• the diastereomers can be separated by chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
• the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
• a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.
• the compounds of Formula I can be made by a process, which involves:
• Step a To a solution of 3-bromo-2-(trifluoromethyl)pyridine (1.0 g, 4.42 mmol), XantPhos (256 mg, 0.442 mmol), Pd 2 (dba)3 (203 mg, 0.221 mmol) in dioxane (12 mL) was added (at RT and under N 2 ) 2-ethylhexyl-3-mercaptopropanoate (1.1 mL, 4.87 mmol) followed by addition of DIPEA (1.55 mL, 8.85 mmol). The resulting solution was stirred in a microwave reactor for 1 h at 110 °C.
• Step b To a solution of 2-ethylhexyl 3-((2-(trifluoromethyl)pyridin-3- yl)thio)propanoate (1.0 g, 2.75 mmol) in THF (8 mL) was added at -78 °C and under N 2 potassium fer?-butoxide (1 M in THF, 8.25 mL, 8.25 mmol). After stirring vigorously at -78 °C for 20 min, the reaction was quenched with K 2 C0 3 aq (2 M, 500 ⁇ ) and the volatiles were removed under reduced pressure.
• Step c To a solution of 2-(trifluoromethyl)pyridine-3-thiol (285 mg, 1.591 mmol), 3-bromo-6-chloropyrazin-2-amine (414 mg, 1.988 mmol), XantPhos (101 mg, 0.175 mmol), and Pd 2 (dba) 3 (72.8 mg, 0.08 mmol) in dioxane (2 mL) was added (at RT and under N 2 ) DIPEA (556 ⁇ , 3.18 mmol). The resulting solution was stirred in a microwave reactor for 1.5 h at 130 °C.
• Step a A suspension of fer?-butyl l-amino-7-azaspiro[3.5]nonane-7- carboxylate (250 mg, 1.04 mmol), phthalic anhydride (193 mg, 1.3 mmol), activated molecular sieves (3 angstroms, 250 mg), and DIPEA (545 ⁇ , 3.12 mmol) in toluene (4 mL) was stirred for 16 h at 105 °C. After cooling to RT, the mixture was filtered through a pad of Celite followed by EtOAc (10 mL) wash.
• Step b A solution of ?er?-butyl l-(l,3-dioxoisoindolin-2-yl)-7- azaspiro[3.5]nonane-7-carboxylate (233 mg, 0.629 mmol) and HC1 (4 M in dioxane, 800 ⁇ , 3.21 mmol) in dioxane (5 mL) was stirred for 16 h at RT. The volatiles were removed on the rotavap to give the HC1 salt of the title compound (195 mg, 0.636 mmol). MS m/z 270.3 (M+H) + .
• Step a A solution of 8-(?er?-butoxycarbonyl)-l-thia-8-azaspiro[4.5]decane-4- carboxylic acid 1,1 -dioxide (prepared from fer?-butyl 4-oxopiperidine-l-carboxylate in 4 steps as described in Carreira et al., Org Lett, 2011, 13, 6134-6136; 2.00 g, 6.00 mmol), diphenyl phosphorazidate (2.0 g, 7.26 mmol), and Et 3 N (1.0 mL, 7.26 mmol) in toluene (37 mL) was stirred for 1.5 h at 115 °C.
• Step b A suspension of fer?-butyl 4-(((benzyloxy)carbonyl)amino)-l-thia-8- azaspiro[4.5]decane-8-carboxylate 1,1-dioxide (570 mg. 1.30 mmol) and Pd/C (10% on charcoal, 138 mg) in THF (8 mL) was vigorously stirred under H 2 atmosphere for 16 h. The reaction was filtered through a plug of Celite followed by EtO Ac (20 mL) wash. The volatiles were removed under reduced pressure to give fer?-butyl 4-amino-l-thia-8-azaspiro[4.5]decane-8-carboxylate 1,1- dioxide which was used in next step without further purification.
• Step c A suspension of fer?-butyl 4-amino-l-thia-8-azaspiro[4.5]decane-8- carboxylate 1,1-dioxide (415 mg, 1.363 mmol), phthalic anhydride (252 mg, 1.704 mmol), and activated molecular sieves (3 angstroms, 500 mg) in toluene (7 mL) was vigorously stirred for 16 h at 115 °C. After cooling to RT, the mixture was filtered through a pad of Celite followed by EtO Ac (10 mL) wash, and the volatiles were removed under reduced pressure.
• Step d A solution of tert-hutyl 4-(l,3-dioxoisoindolin-2-yl)-l-thia-8- azaspiro[4.5]decane-8-carboxylate 1,1-dioxide (385 mg, 0.886 mmol) and HC1 (4 M in dioxane, 2.22 mL, 8.86 mmol) in dioxane (4 mL) was stirred for 16 h at RT.
• Step a A solution of fer?-butyl l-oxo-7-azaspiro[3.5]nonane-7-carboxylate
• Step b A solution of (S)-tert-butyl l-((R)-l,l-dimethylethylsulfinamido)-7- azaspiro[3.5]nonane-7-carboxylate (0.4 g, 1.16 mmol) and TFA (450 5.81 mmol) in DCM (3.5 mL) was stirred for 30 min at 40 °C. Na 2 C0 3 sat. aq. was added until pH 11 and the aqueous mixture was extracted with DCM (3 x 15 mL).
• Step a To a solution of tert-butyl l-oxo-8-azaspiro[4.5]decane-8-carboxylate
• Step b A solution of tert-butyl l-((4-methoxybenzyl)amino)-8- azaspiro[4.5]decane-8-carboxylate (1.1 g, 2.94 mmol) and TFA (2 mL) in DCM (2 mL) was stirred for 15 min at 0 °C. The volatiles were removed under reduced pressure. The resulting residue was diluted with aqueous NaHC0 3 (10 mL) and extracted with EtOAc (4 x 10 mL) to give N-(4-methoxybenzyl)-8-azaspiro[4.5]decan-l-amine (0.8 g, 2.92 mmol) as a colorless oil. MS m/z 275.2 (M+H) + .
• N-(4-methoxybenzyl)-3-azaspiro[5.5]undecan-7-amine was obtained following the above procedure starting from tert-butyl 7-oxo-3-azaspiro[5.5]undecane-3-carboxylate.
• Step a To a solution of tert-butyl l-oxo-8-azaspiro[4.5]decane-8-carboxylate
• Step b To a solution of tert-butyl l-(((R)-l-(4-methoxyphenyl)ethyl)amino)-8- azaspiro[4.5]decane-8-carboxylate (major diastereomer; 431 mg, 1.11 mmol) in DCM (2 mL) was added TFA (2 mL) and stirred for 10 min at RT. The reaction was concentrated with further addition of DCM, then diluted with saturated aqueous NaHC0 3 and extracted with DCM (3 x 20 mL).
• Step a To a solution of tert-butyl 4-oxo-l-oxa-8-azaspiro[4.5]decane-8- carboxylate (prepared from tert-butyl 4-oxopiperidine-l-carboxylate in 3 steps as described in Carreira et al., Org Lett., 2013, 15, 4766-4769; 200 mg, 0.78 mmol), and (R)-l-(4- methoxyphenyl)ethanamine (474 mg, 3.13 mmol) in DCE (1 mL) was added sodium
• Step b A solution of tert-butyl 4-(((R 1 -(4-methoxyphenyl)ethyl)amino)- 1 - oxa-8-azaspiro[4.5]decane-8-carboxylate (major diastereomer, 65 mg, 0.17 mmol) and TFA (2 mL) in DCM (2 mL) stirred for 10 min at RT. The volatiles were removed under reduced pressure, diluted with NaHC0 3 sat. aq. (5 mL), and extracted with DCM (3 x 20 mL).
• Step a Commercially available 2,3-dichloro-4-iodopyridine was converted to
• Step b To a solution of 3-amino-5-chloropyrazine-2-thiol (100 mg, 0.619 mmol), 3-chloro-4-iodopyridin-2-amine (315 mg, 1.238 mmol), XantPhos (35.8 mg, 0.062 mmol), and Pd 2 (dba) 3 (28.3 mg, 0.03 mmol) in dioxane (3 mL) was added (at RT and under N 2 ) DIPEA (324 1.856 mmol). The resulting solution was stirred in a microwave reactor for 2.5 h at 100 °C.
• Step a A solution of 3-bromo-6-chloropyrazin-2-amine (4.95 g, 23.74 mmol) in dioxane (119 mL) was sparged with nitrogen for 10 min. Then, 2-ethylhexyl 3- mercaptopropanoate (3.79 mL, 24.92 mmol), Xantphos (1.37 g, 2.37 mmol), Pd 2 (dba) 3 (1.08 g, 1.19 mmol), and DIPEA (8.29 mL, 47.5 mmol) were added. The resulting mixture was stirred at 105 °C for 24 h and the reaction mixture was filtred through Celite and concentrated.
• Step b To a solution of 2-ethylhexyl 3-((3-amino-5-chloropyrazin-2- yl)thio)propanoate (2.3 g, 6.65 mmol) in THF (33 mL) at -78 °C, potassium fer?-butoxide (1 M in THF, 19.95 mL, 19.95 mmol) was added and the resulting mixture was stirred at -78 °C for 1 h. MeOH (20 mL) was added and the resulting mixture was concentrated.
• Step a To a solution of fer?-butyl 4-hydroxy-2-oxa-8-azaspiro[4.5]decane-8- carboxylate (306 mg, 1.19 mmol), phthalimide (262 mg, 1.78 mmol) and triphenylphosphine (468 mg, 1.78 mmol) in THF (10 mL) was added diisopropylazadicarboxylate (0.374 mL, 1.78 mmol) and stirred 16 h.
• Step b To a solution of racemic fer?-butyl 4-(l,3-dioxoisoindolin-2-yl)-2-oxa-
• Step a A mixture of 2-chloro-3-fluorobenzonitrile (3.15 g, 20.25 mmol), 2- methylpropane-2-thiol (2.283 mL, 20.25 mmol) and Cs 2 C0 3 (6.598 g, 20.25 mmol) in DMF (100 mL) was stirred for 48 h at 22 °C. The reaction mixture was diluted with water (200 mL) and EtOAc (300 mL). EtOAc layer was washed with water (3 x 300 mL), brine (3 x 100 mL), dried over Na 2 S0 4 , filtered and concentrated.
• Ste b A mixture of 3-(?er?-butylthio)-2-chlorobenzonitrile (217 mg, 0.961 mmol) and NaOH (1 N, 2.88 mL, 2.88 mmol) in MeOH (11 mL) was irradiated in a microwave reactor for 35 min at 90 °C. After cooling to RT, the reaction was concentrated and dissolved in MeOH.
• Step c A mixture of 3-(?er?-butylthio)-2-chlorobenzamide (190 mg, 0.779 mmol) and cone. HCl (2.36 mL, 78 mmol) was stirred for 45 min at 85 °C. After cooling to RT, the reaction was concentrated to dryness to yield crude 2-chloro-3-mercaptobenzamide (HCl salt: 156 mg, 0.651 mmol). MS m/z 188 (M+H) + .
• Step a A mixture of fer?-butyl 4-formylpiperidine-l-carboxylate (35.0 g, 164 mmol), lithium fer?-butoxyde (15.77 g, 197 mmol), and allylbromide (11.54 mL, 189 mmol) in DMF (328 mL) was stirred for 1 h at 0 °C. The mixture was poured into a separation funnel containing sat. aq NH 4 C1:H 2 0 (1 : 1 , 500 mL) and it was extracted with Et 2 0 (5 x 50 mL). The combined organic phases were dried over MgS0 4 , filtered, and the volatiles were removed under reduced pressure.
• Step b To a solution of fer?-butyl 4-allyl-4-formylpiperidine-l-carboxylate (24 g, 95 mmol) in THF (300 mL) was added (at -78 °C and under N 2 ) vinyl magnesium bromide (1 M in THF, 118 mL, 118 mmol). The resulting solution was slowly warmed up to RT within 1 h. The mixture was poured into a separation funnel containing sat. aq NH 4 C1 (250 mL) and it was extracted with EtOAc (4 x 50 mL).
• Step c A mixture of fer?-butyl 4-allyl-4-(l-hydroxyallyl)piperidine-l- carboxylate (26.7 g, 95 mmol) and Dess-Martin periodinane (44.3 g, 105 mmol) in DCM (380 mL) was stirred for 1 h at RT. The mixture was poured into a separation funnel containing sat. aq NaHC0 3 :Na 2 S0 3 (1 :1, 300 mL) and it was extracted with DCM (4 x 50 mL). The combined organic phases were dried over MgSO-t, filtered, and the volatiles were removed under reduced pressure to provide a white solid.
• Step d To a solution of fer?-butyl 4-acryloyl-4-allylpiperidine-l -carboxylate
• Step a To a suspension of tert-butyl l-oxo-8-azaspiro[4.5]dec-2-ene-8- carboxylate (4.2 g, 16.71 mmol) and Cul (6.37 g, 33.4 mmol) in Et 2 0 (100 mL) was added (at 0 °C and under N 2 ) MeLi (1.6 M in THF, 31.3 mL, 50.1 mmol). After stirring for 90 min at 0 °C, the mixture was poured into a separation funnel containing sat. aq NH 4 C1 and it was extracted with EtOAc (3 x 15 mL).
• Step b A solution of fer?-butyl 3-methyl-l-oxo-8-azaspiro[4.5]dec-2-ene-8- carboxylate (502 mg, 1.878 mmol), titanium(IV) ethoxide (1.57 mL, 7.51 mmol), and 2- methylpropane-2-sulfinamide (455 mg, 3.76 mmol) in THF (12.5 mL) was stirred for 16 h at 65 °C. After cooling to 0 °C, MeOH (3 mL) was added followed by lithium borohydride (123 mg, 5.63 mmol). The resulting mixture was stirred at 0 °C for 1 h. sat.
• Step a A mixture of fer?-butyl 3-methyl-l-oxo-8-azaspiro[4.5]dec-2-ene-8- carboxylate (4.23 g, 15.82 mmol) and TFA (17 mL) in DCM (80 mL) was stirred for 30 min at RT. The volatiles were removed under reduced pressure. A mixture of the resulting residue, DIPEA (13.82 mL, 79 mmol), and benzyl chloroformate (3.39 mL, 23.73 mmol) in DCM (80 mL) was stirred for 16 h at RT. The mixture was poured into a separation funnel containing sat.
• Step b Benzyl 3-methyl-l-oxo-8-azaspiro[4.5]decane-8-carboxylate (4.58 g,
• Step c A solution of (R)-benzyl 3-methyl-l-oxo-8-azaspiro[4.5]decane-8- carboxylate (2.02 g, 6.70 mmol), titanium(IV) ethoxide (5.62 mL, 26.8 mmol), and (R)-2- methylpropane-2-sulfinamide (1.625 g, 13.4 mmol) in THF (67 mL) was stirred for 16 h at 65 °C. After cooling to -78 °C, MeOH (12 mL) was added followed by lithium borohydride (0.438 g, 20.11 mmol). The resulting mixture was stirred for 16 h at -78 °C to RT.
• Step c from enantiomer: The same procedure was followed starting from (S)- benzyl 3-methyl-l-oxo-8-azaspiro[4.5]decane-8-carboxylate to give (lR,35)-benzyl 1-((R)-1 ,1- dimethylethylsulfinamido)-3-methyl-8-azaspiro[4.5]decane-8-carboxylate.
• Step a A mixture of CuCl (142 mg, 1.432 mmol), (5)-TolBINAP (972 mg,
• Step b A solution of (R)-tert-butyl 3-((?er?-butyldimethylsilyl)oxy)-l-oxo-8- azaspiro[4.5]decane-8-carboxylate (8 g, 20.86 mmol), titanium(IV) ethoxide (17.49 mL, 83.0 mmol), and (R)-2-methylpropane-2-sulfinamide (5.06 g, 41.7 mmol) in THF (100 mL) was stirred for 16 h at 65 °C. After cooling to -78 °C, MeOH (15 mL) was added followed by lithium borohydride (1.363 g, 62.6 mmol).
• Step a A mixture of (lR,3R)-ter?-butyl 3-((?er?-butyldimethylsilyl)oxy)-l-((R)- l,l-dimethylethylsulfinamido)-8-azaspiro[4.5]decane-8-carboxylate (3.84 g, 7.86 mmol) and TBAF (1 M in THF; 8.64 mL, 8.64 mmol) in THF (40 mL) was stirred for 30 min at RT.
• Step b To a solution of (lR,3R)-ter?-butyl 1-((R)-1,1- dimethylethylsulfinamido)-3-hydroxy-8-azaspiro[4.5]decane-8-carboxylate (3.0 g, 8.01 mmol), triphenylphosphine (4.2 g, 16.02 mmol), and isoquinoline-l-carboxylic acid (4.16 g, 24.03 mmol) in THF (80 mL) was added DIAD (3.1 mL, 16.02 mmol). The resulting mixture was stirred for 1 h at RT.
• the reaction was diluted with EtOAc (50 mL), filtered through a pad of Celite, poured into a separation funnel containing sat. aq NaHCC ⁇ and extracted with EtOAc (3 x 25 mL). The combined organic phases were dried over MgS0 4 , filtered and the volatiles were removed under reduced pressure.
• Step c A mixture of (2S,4R)-8-(ter?-butoxycarbonyl)-4-((R)-l,l- dimethylethylsulfinamido)-8-azaspiro[4.5]decan-2-yl isoquinoline-l-carboxylate (3.65 g, 6.89 mmol) and lithium hydroxide (2.95 g, 68.9 mmol) in THF:H 2 0 (1 : 1, 70 mL) was stirred for 2 h at RT. The mixture was poured into a separation funnel containing sat. aq NH 4 C1 and it was extracted with EtOAc (3 x 15 mL).
• the reaction was diluted with EtOAc (50 mL), filtered through a pad of Celite, poured into a separation funnel containing sat. aq NaHC0 3 , and extracted with EtOAc (3 x 10 mL). The combined organic phases were dried over MgS0 4 , filtered, and the volatiles were removed under reduced pressure.
• Step a A mixture of fer?-butyl 3 -((fer?-butyldimethylsilyl)oxy)- 1 -( 1 , 1 - dimethylethylsulfinamido)-8-azaspiro[4.5]decane-8-carboxylate (365 mg, 0.746 mmol) and HC1 (4 M in dioxane, 1.86 mL, 7.46 mmol) in MeOH (4 mL) was stirred for 1 h at 40 °C. After cooling to RT, the volatiles were removed under reduced pressure to give a white solid. MS mlz 171.1 (M+H) + .
• Step b A mixture of fer?-butyl l-((fer?-butoxycarbonyl)amino)-3-hydroxy-8- azaspiro[4.5]decane-8-carboxylate (275 mg, 0.742 mmol) and Dess-Martin periodinane (472 mg, 1.113 mmol) in DCM (7.5 mL) was stirred for 2 h at 0 °C. The mixture was poured into a separation funnel containing sat. aq NaHC0 3 and it was extracted with DCM (3 x 10 mL). The combined organic phases were dried over MgSO-t, filtered and the volatiles were removed under reduced pressure.
• Step c A mixture of tert-butyl l-((fer?-butoxycarbonyl)amino)-3-oxo-8- azaspiro[4.5]decane-8-carboxylate (95 mg, 0.258 mmol) and DeoxoFluor (190 ⁇ ⁇ , 1.031 mmol) in DCM (1 mL) was stirred for 48 h at 50 °C. The mixture was poured into a separation funnel containing sat. aq NaHCC ⁇ /ice and it was extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over MgS0 4 , filtered and the volatiles were removed under reduced pressure.
• Step a A solution of diisopropylamine (0.320 mL, 2.245 mmol) in THF (4 mL) was cooled to -78 °C and treated with «-butyllithium (1.3 mL, 2.080 mmol) then stirred for 5 min at -78 °C and warmed to 0 °C giving a solution of LDA to be used subsequently.
• Step b A solution of fer?-butyl 4-allyl-4-cyanopiperidine-l-carboxylate (22 mg, 0.088 mmol) in DCM (1.5 mL) and NaOH (2.5 M in MeOH, 0.176 mL, 0.439 mmol) was aerated with ozone (diffusing aerator) at -78°C for 30 minutes. The reaction was purged with oxygen then partitioned between water and DCM. The phases were separated, the organic collected and the aqueous extracted with DCM (2 x 5 mL). The combined organic phases were concentrated under reduce pressure. The resulting residue was taken up in MeOH and stirred for 24 h at 65 °C.
• Step c A solution of fert-butyl 4-cyano-4-(2-methoxy-2-oxoethyl)piperidine-
• Step a A solution of fer?-butyl 4-hydroxy-2-oxa-8-azaspiro[4.5]decane-8- carboxylate (544 mg, 2.1 1 mmol) and Dess-Martin periodinane (1.39 g, 3.17 mmol) in DCM (10 mL) was stirred for 2 h at 0 °C. Sat. aq NaHC0 3 :sat. aq Na 2 S 2 0 3 (1 : 1, 10 mL) was added, the organic phase was separated and the aqueous phase was extracted with DCM (3 x 10 mL). The combined organic phases were dried over Na 2 S0 4 , filtered and the volatiles were removed under reduced pressure.
• Step b A solution of tert-butyl 4-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate (220 mg, 0.86 mmol), titanium(IV) ethoxide (725 ⁇ ⁇ , 3.45 mmol), and (R)-2- methylpropane-2-sulfinamide (209 mg, 1.72 mmol) in THF (4 mL) was stirred for 1 h at 90 °C. After cooling to 0 °C, lithium borohydride (23 mg, 1.06 mmol) was added. After stirring for 30 min, the reaction mixture was quenched by addition of MeOH. The volatiles were removed under reduce pressure.
• Step a To a solution of fer?-butyl l-oxo-8-azaspiro[4.5]decane-8-carboxylate
• Step b A solution of tert-butyl 2-methyl-l-oxo-8-azaspiro[4.5]decane-8- carboxylate (267 mg, 0.999 mmol), titanium(IV) ethoxide (837 ⁇ ,, 3.99 mmol), and (R)-2- methylpropane-2-sulfinamide (242 mg, 1.997 mmol) in THF (10 mL) was stirred for 24 h at 85 °C. After cooling to -78 °C, MeOH (12 mL) was added followed by lithium borohydride (65.3 mg, 3.00 mmol). The resulting mixture was stirred at -78 °C to RT for 16 h. Sat.
• Step a To a solution of of fer?-butyl 4-oxo-2-oxa-8-azaspiro[4.5]decane-8-
• Step b A solution of tert-butyl 3-methyl-4-oxo-2-oxa-8-azaspiro[4.5]decane-8- carboxylate (318 mg, 1.181 mmol), titanium(IV) ethoxide (990 ⁇ , 4.72 mmol), and (R)-2- methylpropane-2-sulfinamide (286 mg, 2.361 mmol) in THF (4 mL) was stirred for 90 min at 90 °C. After cooling to 0 °C, lithium borohydride (65.3 mg, 3.00 mmol) was added in one portion and the resulting mixture was stirred stirred for 16 h at RT. Sat.
• Step c The diastereomers were separated by chiral SFC as follows: column:
• Step a To a -10 °C solution of diisopropylamine (23.4 mL, 166 mmol) in THF
• Step b To a solution of crude 1 -tert-butyl 4-ethyl 4-((2S)-2-((tert- butyldimethylsilyl)oxy)-l-hydroxypropyl)piperidine-l,4-dicarboxylate (95 g, 214 mmol) in THF (600 mL) was added portionwise LiBH 4 (7.0 g, 321 mmol) and the resulting mixture was stirred for 16 h at RT. After cooling to 0 °C, sat. aq NaHC0 3 :H 2 0 (1 :2, 150 mL) was added and the resulting mixture was vigorously stirred until no more bubbling was observed.
• Step c A solution of tert-butyl 4-((25)-2-((?ert-butyldimethylsilyl)oxy)-l - hydroxypropyl)-4-(2-hydroxyethyl)piperidine-l -carboxylate (64.8 g, 161 mmol) and TBAF (1 M in THF, 242 mL, 242 mmol) in THF (500 mL) was stirred for 2 h at RT. Sat. aq NaHC0 3 :H 2 0 (1 :2, 150 mL) were added, the phases were separated, and the aqueous phase was further extracted with EtOAc (3 x 100 mL).
• Step d To a 0 °C suspension of NaH (10.60 g, 424 mmol) in THF (600 mL) was added dropwise a solution of fer?-butyl 4-((25)-l,2-dihydroxypropyl)-4-(2- hydroxyethyl)piperidine-l -carboxylate (35.06 g, 121 mmol) and TsCl (23.10 g, 121 mmol) in THF (200 mL). The resulting mixture was stirred for 1 h at 0 °C. Sat.
• Step e A solution of (35)-?er?-butyl 4-hydroxy-3-methyl-2-oxa-8- azaspiro[4.5]decane-8-carboxylate (32.19 g, 119 mmol) and Dess-Martin periodinane (67.4 g, 154 mmol) in DCM (300 mL) was stirred for 2 h at 0 °C.
• Step f A solution of (3S)-fer?-butyl 3-methyl-4-oxo-2-oxa-8- azaspiro[4.5]decane-8-carboxylate (22.52 g mg, 84 mmol), titanium(IV) ethoxide (70.1 mL, 334 mmol), and (R)-2-methylpropane-2-sulfinamide (21 g, 173 mmol) in THF (300 mL) was stirred for 21 h at 90 °C.
• Step g The diastereomers were separated by chiral SFC as follows: column:
• Step a A mixture of (2R,4R)-4-amino-8-azaspiro[4.5]decan-2-ol
• Step b A mixture of (lR,3R)-benzyl l-(((benzyloxy)carbonyl)amino)-3- hydroxy-8-azaspiro[4.5]decane-8-carboxylate (440 mg, 1.003 mmol) and Dess-Martin periodinane (638 mg, 1.505 mmol) in DCM (6 ml.) was stirred for 1 h at 0 °C and for 18 h at RT. The reaction mixture was diluted with sat, aq NaHC0 3 ;sat. aq Na 2 S 2 0 3 (1 : 1, 25 mL).
• Step c To a solution of MeLi (1.2 M in THF, 2.61 mL, 3.13 mmol) in THF (15 mL) was added dropwise (R)-benzyl l-(((benzyloxy)carbonyl)amino)-3-oxo-8- azaspiro[4.5]decane-8-carboxylate (415 mg, 0.951 mmol) in THF (5 mL) at -30 to -40 °C. The resulting mixture was stirred for 20 min at -30 to -40 °C. The mixture was dilute with NaHS0 4 (10% solution in H 2 0), diluted with EtOAc, and allowed to warm up to RT under vigrously stirring.
• Step d A mixture of diastereomer A (50 mg, 0.11 mmol) and Pd/C (10 wt.%;
• Step a To a solution of 5,6-dichloropyridin-2-amine (590 mg, 3.62 mmol) in
• Step b To a solution of diisopropylamine (1 mL, 7.07 mmol) in THF (5 mL) was added «-BuLi (2.5 M in hexanes, 2.83 mL, 7.07 mmol) at -78 °C and the resulting solution was stirred for 1 h at this temperature. 7er?-butyl (5,6-dichloropyridin-2-yl)carbamate (930 mg, 3.53 mmol) in THF (5 mL) was added at -78 °C.
• Step c A mixture of fert-butyl (5,6-dichloro-4-iodopyridin-2-yl)carbamate (610 mg, 1.57 mmol), sodium 3-amino-5-chloropyrazine-2-thiolate (302 mg, 1.65 mmol), Pdi(dba)3 (72 mg, 0.08 mmol), Xantphos (91 mg, 0.16 mmol), and DIPEA (0.55 mL, 3.14 mmol) in dioxane (7.8 mL) was stirred for 8 h at 1 10 °C. After cooling to RT, the reaction mixture was filtered through a pad of Celite and the volatiles were removed under reduced pressure.
• Step d A mixture of fer?-butyl (4-((3-amino-5-chloropyrazin-2-yl)thio)-5,6- dichloropyridin-2-yl)carbamate (470 mg, 1.11 mmol) and HQ (4 M in dioxane, 5.56 mL, 22.24 mmol) was stirred for 1 h at RT. The volatiles were removed under reduced pressure to give 3-((6- amino-2,3-dichloropyridin-4-yl)thio)-6-chloropyrazin-2-amine dihydrochloride (411 mg, 1.04 mmol) which was used without further purification. MS m/z 324.0 (M+H) + .
• Step a A solution of 6-chloro-3-((2-(trifluoromethyl)pyridin-3-yl)thio)pyrazin-
• Step a A solution of 6-chloro-3-((2,3-dichlorophenyl)thio)pyrazin-2-amine
• Step a A mixture of 6-chloro-3-((2-(trifluoromethyl)pyridin-3-yl)thio)pyrazin-
• Step b A solution of (R)-N-((5)-7-(6-amino-5-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrazin-2-yl)-7-azaspiro[3.5]nonan-l-yl)-2-methylpropane-2-sulfinamide (142 mg, 0.376 mmol) and HQ (4 M in dioxane, 414 ⁇ , 1.66 mmol) in DCM (1.4 mL) was stirred for 20 min at 40 °C. After cooling to RT, HC1 (1 M in H 2 0) was added and the resulting aqueous mixture was extracted with DCM.
• Step a To a solution of 6-chloro-3-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrazin-2-amine (1.2 g, 2.119 mmol) in DCM (30 mL) was added at 0 °C NBS (745 mg, 4.19 mmol) in one portion. The resulting mixture was stirred vigorously for 30 min at 0 °C and for 1 h at RT. The clear solution was quenched with water and extracted with DCM. The combined organic layers were subsequently washed with water, brine, dried over Na 2 S0 4 , filtered and concentrated.
• Step b A mixture of 5-bromo-6-chloro-3-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrazin-2-amine (750 mg, 1.945 mmol) and copper(I) cyanide (348 mg, 3.89 mmol) in DMF (7 mL) was stirred for 14 h at 120 °C. After cooling to RT, the reaction was filtered through a pad of Celite followed by MeOH (50 mL) wash.
• Step c A mixture of 5-amino-3-chloro-6-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrazine-2-carbonitrile (52 mg, 0.157 mmol) and (5)-N-((R)-l-(4-methoxyphenyl)ethyl)-8- azaspiro[4.5]decan-l-amine (90 mg, 0.314 mmol) in DIPEA (0.246 mL) was stirred for 1 h at 135 °C.
• Step e A solution of 5-amino-3-((5)-l-(((R)-l -(4- methoxyphenyl)ethyl)amino)-8-azaspiro[4.5]decan-8-yl)-6-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrazine-2-carboxamide (79 mg, 0.132 mmol) in TFA (1.2 mL, 15.76 mmol) was stirred in a microwave reactor at 100 °C until no starting material remained (3 h, monitored by LCMS).
• Step a A mixture of 3-chloro-l,2,4-triazin-5-amine (70 mg, 0.536 mmol), (S)-
• N-((R)-l-(4-methoxyphenyl)ethyl)-8-azaspiro[4.5]decan-l-amine (247 mg, 0.644 mmol), and N- methylmorpholine (177 ⁇ ⁇ , 1.609 mmol) in MeCN (1 mL) and NMP (0.1 mL) was irradiated in a microwave reactor for 45 min at 90 °C.
• Step b To a solution of (5)-8-(5-amino-l,2,4-triazin-3-yl)-N-((R)-l-(4- methoxyphenyl)ethyl)-8-azaspiro[4.5]decan-l-amine (194 mg, 0.507 mmol) in DCM (8 mL) was added, at 0 °C, NBS (97 mg, 0.543 mmol) in one portion. After stirring for 20 min at 0 °C, the clear solution was quenched with few drops of Na 2 C0 3 aq. and it was extracted with DCM. The combined organic layer was dried over MgSO-t, filtered and the volatiles were removed under reduced pressure.
• Step c A mixture of (5)-8-(5-amino-6-bromo-l,2,4-triazin-3-yl)-N-((R)-l-(4- methoxyphenyl)ethyl)-8-azaspiro[4.5]decan-l-amine (54.1 mg, 0.117 mmol), 2- (tafluoromethyl)pyridine-3 -thiol (21 mg, 0.117 mmol), XantPhos (7.46 mg, 0.013 mmol), Pd 2 (dba) 3 (5.37 mg, 0.0058 mmol), and DIPEA (0.041 mL, 0.234 mmol) in dioxane (1 mL) was stirred in a microwave reactor for 1.5 h at 130 °C.
• Step d A solution of (5)-8-(5-amino-6-((2-(trifluoromethyl)pyridin-3-yl)thio)- l,2,4-triazin-3-yl)-N-((R)-l-(4-methoxyphenyl)ethyl)-8-azaspiro[4.5]decan-l-amine (65 mg, 0.116 mmol) in TFA (1.253 mL, 16.26 mmol) was stirred at 100 °C until no starting material remained (1.5 h, monitored by LC MS), the volatiles were removed under reduced pressure, the resulting residue was diluted with water, and it was extracted with Et 2 0 (3 x 10 mL).
• the aqueous layer was basified to pH 12 using NH 4 OH (28% in water), and it was extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine, dried over Na 2 S0 4 , filtered and the volatiles were removed under reduced pressure. The resulting residue was purified by HPLC (gradient elution 25-50% acetonitrile in water, 5 mM NH 4 OH modifier) to give (5)-8-(5-amino-6- ((2-(trifluoromethyl)pyridin-3-yl)thio)-l,2,4-triazin-3-yl)-8-azaspiro[4.5]decan-l-amine (14.5 mg, 0.032 mmol).
• Step a A mixture of 2-(trifluoromethyl)pyridine-3 -thiol (150 mg, 0.837 mmol),
• Step b A mixture of 2-chloro-5-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrimidin-4-amine (70 mg, 0.228 mmol) and (5)-N-((R)-l-(4-methoxyphenyl)ethyl)-8- azaspiro[4.5]decan-l-amine (105 mg, 0.274 mmol) in DIPEA (0.359 mL) was stirred in a microwave reactor for 1.5 h at 135 °C.
• Step c A solution of (5)-8-(4-amino-5-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrimidin-2-yl)-N-((R)-l-(4-methoxyphenyl)ethyl)-8-azaspiro[4.5]decan-l-amine (128 mg, 0.229 mmol) in TFA (2.471 mL, 32.1 mmol) was stirred at 100 °C until no starting material remained (1.5 h, monitored by LCMS), the volatiles were removed under reduced pressure, the resulting residue was diluted with water, and it was then extracted with Et 2 0 (3 x 10 mL).
• the aqueous layer was basified to pH 12 using NH 4 OH (28% in water), and it was extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine, dried over Na 2 S0 4 , filtered and the volatiles were removed under reduced pressure. The resulting residue was purified by HPLC (gradient elution 35-60% acetonitrile in water, 5 mM NH 4 OH modifier), to give (5)-8- (4-amino-5-((2-(trifluoromethyl)pyridin-3-yl)thio)pyrimidin-2-yl)-8-azaspiro[4.5]decan-l -amine (32 mg, 0.072 mmol).
• Step a A solution of 5-amino-3-chloropyrazine-2-carbonitrile (1.55 g, 10.0 mmol) and (R)-N-((R)-l-(4-methoxyphenyl)ethyl)-8-azaspiro[4.5]decan-l-amine (2.88 g, 10.0 mmol) in DIPEA (10 ⁇ ,) and ⁇ (5 mL) was stirred for 16 h at 110 °C. After cooling to RT, the reaction mixture was poured into a separation funnel containing NaHCC ⁇ aq. and it was extracted with EtOAc. The combined organic phases were dried over MgS0 4 , filtered and the volatiles were removed under reduced pressure.
• Step b (Note: This reaction was run in 4 batches of 500 mg each).
• Step c A solution of 5-amino-3-((R)-l-(((R)-l -(4- methoxyphenyl)ethyl)amino)-8-azaspiro[4.5]decan-8-yl)pyrazine-2-carboxamide (615 mg, 1.45 mmol) in TFA (11 mL) was stirred for 1 h at 100 °C. The volatiles were removed under reduced pressure. A solution of the resulting residue, DIPEA (1.2 mL, 6.89 mmol), and Boc 2 0 (330 mg, 1.516 mmol) in DCM (15 mL) was stirred for 2 h at RT.
• Step d A solution of (R)-fert-butyl (8-(6-amino-3-carbamoylpyrazin-2-yl)-8- azaspiro[4.5]decan-l-yl)carbamate (538 mg, 1.378 mmol), and NBS (270 mg, 1.516 mmol) in DCM (5 mL) was stirred for 20 min at 0 °C. The reaction mixture was quenched with MeOH (2 mL) and stirred for 20 min at RT. The resulting mixture was poured into a separation funnel containing aq NaHC0 3 . and it was extracted with DCM.
• Step e To a solution of (R)-fert-butyl (8-(6-amino-5-bromo-3- carbamoylpyrazin-2-yl)-8-azaspiro[4.5]decan-l-yl)carbamate (627 mg, 1.336 mmol), XantPhos (77 mg, 0.134 mmol), and Pd 2 (dba) 3 (61.2 mg, 0.067 mmol) in dioxane (3 mL) was added (at RT and under N 2 ) 2-ethylhexyl-3-mercaptopropanoate (334 ⁇ ⁇ , 1.469 mmol) followed by addition of DIPEA (467 ⁇ , 2.67 mmol).
• Step f To a solution of 2-ethylhexyl 3-((3-amino-5-((R)-l-((?ert- butoxycarbonyl)amino)-8-azaspiro[4.5]decan-8-yl)-6-carbamoylpyrazin-2-yl)thio)propanoate (574 mg, 0.946 mmol) in THF (3 mL) was added (at -78 °C and under N 2 ) potassium tert- butoxide (1 M in THF, 2.84 mL, 2.84 mmol). After stirring vigorously at -78 °C for 10 min, the reaction was quenched with K 2 C0 3 aq.
• Step g To a solution of (R)-fert-butyl (8-(6-amino-3-carbamoyl-5- mercaptopyrazin-2-yl)-8-azaspiro[4.5]decan-l-yl)carbamate (88 mg, 0.208 mmol), 3-chloro-4- iodo-2-(trifluoromethyl)pyridine (80 mg, 0.260 mmol), XantPhos (12.1 mg, 0.021 mmol), and Pd 2 (dba) 3 (9.6 mg, 0.01 mmol) in dioxane (0.5 mL) was added (at RT and under N 2 ) DIPEA (110 ⁇ , 0.625 mmol).
• Step a To a suspension of 6-chloro-3-((3-chloropyridin-4-yl)thio)pyrazin-2- amine (53 mg, 0.194 mmol) in DIPEA (2 mL) was added (R)-2-methyl-N-((R)-8- azaspiro[4.5]decan-l-yl)propane-2-sulfinamide (65 mg, 0.252 mmol). The resulting mixture was stirred at 90 °C for 10 h and then concentrated.
• Step b To a solution of (R)-N-((R)-8-(6-amino-5-((3-chloropyridin-4- yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-l-yl)-2-methylpropane-2-sulfinamide (40 mg, 0.081 mmol) in DCM (0.8 mL), a solution of HC1 (4 M in dioxane, 101 ⁇ , 0.404 mmol) was added and the resulting mixture was stirred at 40 °C for 1 h. An aquous solution of HC1 (2 M, 2 mL) was added and the resulting mixture was extracted with DCM (2x).
• Step a To a suspension of 6-chloro-3-((2-chloropyridin-3-yl)thio)pyrazin-2- amine (85 mg, 0.311 mmol) in DIPEA (1.6 mL), was added (R)-2-methyl-N-((R)-8- azaspiro[4.5]decan-l-yl)propane-2-sulfinamide (105 mg, 0.405 mmol). The resulting mixture was stirred at 90 °C for 10 h and then concentrated. The crude was purified by silica
• Step b To a solution of (R)-N-((R)-8-(6-amino-5-((2-chloropyridin-3- yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-l-yl)-2-methylpropane-2-sulfinamide (66 mg, 0.133 mmol) in DCM (2 mL), was added a solution of HQ (4 M in dioxane, 167 ⁇ ⁇ , 0.667 mmol) and the resulting mixture was stirred at 40 °C for 1 h. An aqueous solution of HC1 (2 M, 2 mL) was added and the resulting mixture was extracted with DCM (2x).
• Step a To a suspension 6-chloro-3-((2,3-dichloropyridin-4-yl)thio)pyrazin-2- amine (34 mg, 0.111 mmol) in DIPEA (0.55 mL), (R)-2-methyl-N-((R)-8-azaspiro[4.5]decan-l- yl)propane-2-sulfinamide (37 mg, 0.144 mmol) was added. The resulting mixture was stirred at 90 °C for 10 h and then concentrated.
• Step b To a solution of (R)-N-((R)-8-(6-amino-5-((2,3-dichloropyridin-4- yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-l-yl)-2-methylpropane-2-sulfinamide (20 mg, 0.038 mmol) in DCM (0.38 mL), was added a solution of HC1 (4 M in dioxane, 47 ⁇ , 0.189 mmol) and the resulting mixture was stirred at 40 °C for 1 h. The reaction mixture was concentrated and dissolved in MeOH.
• Step a To a suspension of 6-chloro-3-((2,3-dichloropyridin-4-yl)thio)pyrazin-
• Step b To a solution of (R)-N-((5)-7-(6-amino-5-((2,3-dichloropyridin-4- yl)thio)pyrazin-2-yl)-7-azaspiro[3.5]nonan-l-yl)-2-methylpropane-2-sulfinamide (20 mg, 0.039 mmol) in DCM (0.38 mL), was added a solution of HC1 (4 M in dioxane, 47 ⁇ , 0.189 mmol) and the resulting mixture was stirred at 40 °C for 1 h. The reaction mixture was concentrated and dissolved in MeOH.
• Step a To a suspension 3 -((3 -amino-2-chlorophenyl)thio)-6-chloropyrazin-2- amine (60 mg, 0.209 mmol) in DIPEA (1.5 mL) was added (R)-2-methyl-N-((R)-8- azaspiro[4.5]decan-l-yl)propane-2-sulfinamide (70 mg, 0.272 mmol). The resulting mixture was stirred at 90 °C for 10 h and then concentrated.
• Step b To a solution of (R)-N-((R)-8-(6-amino-5-((3-amino-2- chlorophenyl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-l-yl)-2-methylpropane-2-sulfinamide (31 mg, 0.061 mmol) in DCM (0.6 mL) was added a solution of HC1 (4 M in dioxane, 76 ⁇ ,, 0.304 mmol) and the resulting mixture was stirred at 40 °C for 1 h. An aqueous solution of HC1 (2 M, 2 mL) was added and the resulting mixture was extracted with DCM (2x).
• Step a To a RT solution of fer?-butyl 2-oxo-l,8-diazaspiro[4.5]decane-8- carboxylate (300 mg, 1.180 mmol) in dichloromethane (3 mL) was added phosphorus pentasulfide (110 mg, 0.495 mmol) followed by hexamethyldisiloxane (2.256 mL, 10.62 mmol). The reaction was stirred for 3 h at RT then diluted with EtOAc and filtered through Celite. The filtrate was concentrated under reduced pressure.
• Step b To a solution of l-thioxo-2,8-diazaspiro[4.5]decane-8-carboxylate (100 mg, 0.370 mmol) in THF (3 mL) was added dropwise iodomethane (0.231 mL, 3.70 mmol). The resulting solution was stirred at RT for 16 h. Throughout the course of the reaction the mixture slowly became more yellow in color and resulted in a light yellow precipitate after stirring the allotted reaction time. The reaction mixture was concentrated and dried under vacuum giving a yellow solid.
• Step c To a solution of fer?-butyl l-amino-2,8-diazaspiro[4.5]dec-l-ene-8- carboxylate (86 mg, 0.339 mmol) in DCM (3 mL) was added HC1 in dioxane (4 M, 0.500 mL, 2.0 mmol) at RT and the reaction stirred for 16 h. The reaction mixture was concentrated and residue was triturated from acetonitrile and filtered giving 2,8-diazaspiro[4.5]dec-l-en-l-amine (57.7 mg, 0.254 mmol) as a tan solid.
• Step d To a suspension of 6-chloro-3-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrazin-2-amine (250 mg, 0.815 mmol) and 2,8-diazaspiro[4.5]dec-l-en-l-amine (210 mg, 1.371 mmol) in N-methyl-2-pyrrolidinone (4 mL) was added DIPEA (1.4 mL, 8.02 mmol) and the reaction heated to 140 °C for 16 h. The resulting dark mixture was cooled to RT and diluted with EtO Ac and water. The layers were partitioned and the organic discarded.
• the aqueous layer was extracted with 20% isopropanol/chloroform mixture (2 x 30 mL), the combined organics dried over Na 2 S0 4 , filtered and concentrated.
• the crude residue was purified using preparative HPLC (gradient elution, 5 to 40% ACN in water, 0.1% TFA modifier) and half the pooled fractions were lyophilized giving 8-(6-amino-5-((2-(trifluoromethyl)pyridin-3-yl)thio)pyrazin-2-yl)-2,8- diazaspiro[4.5]dec-l-en-l-amine (TFA salt: 61.4 mg, 0.082 mmol).
• Step a To a solution of 2,6-dichloropyridine-3-carboxamide (0.728 g, 3.81 mmol) in 1-methyl pyrrolidinone (7 mL) was added N-methyl morpholine (1.14 mL, 10.40 mmol) and (3 ⁇ 4 -N-((R)-l-(4-methoxyphenyl)ethyl)-8-azaspiro[4.5]decan-l-amine (1 g, 3.47 mmol). The resulting mixture was heated to 100 °C under refluxing conditions for 24 h. The reaction mixture was diluted with ethyl acetate, treated with concentrated sodium bicarbonate and filtered.
• Step b To a solution of 6-chloro-2-((R)-l-(((R)-l-(4- methoxyphenyl)ethyl)amino)-8-azaspiro[4.5]decan-8-yl)nicotinamide (242 mg, 0.546 mmol), in toluene (11 mL), was added Pd 2 (dba) 3 (97 mg, 0.169 mmol), and (oxybis(2,l- phenylene))bis(diphenylphosphine) (103 mg, 0.191 mmol).
• reaction mixture was sparged with nitrogen, and benzophenone imine (0.11 mL, 0.656 mmol) and potassium fer?-butoxide (0.710 mL, 1 M in tetrahydrofuran, 0.710 mmol) were added under nitrogen.
• the reaction mixture was heated to 80 °C for 2 h, and the mixture was allowed to cool to RT, filtered through a pad of Celite, and washed with ethyl acetate.
• Step c To a suspension of 6-((diphenylmethylene)amino)-2-((R)-l-(((R)-l-(4- methoxyphenyl)ethyl)amino)-8-azaspiro[4.5]decan-8-yl)nicotinamide (130 mg, 0.221 mmol) in THF (6 mL), was added HC1 (2 M, 0.1 mL, 0.200 mmol) and the resulting solution stirred at RT for 30 minutes.
• Step d A solution of 6-amino-2-((R)-l-(((R)-l-(4- methoxyphenyl)ethyl)amino)-8-azaspiro[4.5]decan-8-yl)nicotinamide (199 mg, 0.470 mmol) in trifluoroacetic acid (3 mL) was heated to 100 °C for 30 min. The mixture was concentrated under reduced pressure and the residue was used in the next step without further purification. (R)-6- amino-2-(l-amino-8-azaspiro[4.5]decan-8-yl)nicotinamide. MS m/z 290.2 (M+H) + .
• Step e To a solution of (R)-6-amino-2-(l-amino-8-azaspiro[4.5]decan-8- yl)nicotinamide in dichloromethane (2 mL) was added triethylamine (0.196 mL, 1.410 mmol) and di-fer?-butyl dicarbonate (113 mg, 0.517 mmol) and the resulting mixture was stirred for 2 h at RT. The reaction mixture was concentrated under reduced pressure, and the residue purified by silica chromatography (0 to 50% gradient of ethyl acetate/heptane, containing 0.25%
• Step f To a solution of (R)-fert-butyl (8-(6-amino-3-carbamoylpyridin-2-yl)-8- azaspiro[4.5]decan-l-yl)carbamate (136 mg, 0.349 mmol) in dichloromethane (5 mL), cooled on an ice bath, was added N-iodosuccinimide (86 mg, 0.384 mmol). The resulting mixture was stirred at 5 °C for 2 h. The reaction was quenched by adding 2 mL of methanol, and the mixture allowed to warm up to RT. The solvents were removed under reduced pressure.
• Step g To a solution of (R)-fert-butyl (8-(6-amino-3-carbamoyl-5-iodopyridin-
• Step h To a solution of (R)-fert-butyl (8-(6-amino-3-carbamoyl-5-((2-)
• Step a A mixture of 2-chloro-3-mercaptobenzamide (HC1 salt, 145 mg, 0.647 mmol), 3-bromo-6-chloropyrazin-2-amine (299 mg, 1.436 mmol), copper (I) iodide (49.3 mg, 0.259 mmol), potassium phosphate (412 mg, 1.941 mmol), and 1 ,10-phenanthroline (58.3 mg, 0.324 mmol) in dioxane (5 mL, degassed) was stirred in a microwave reactor for 4 h at 130 °C. After cooling to RT, the reaction was filtered through a pad of Celite followed by EtOAc (50 mL) wash.
• Step b A mixture of 3 -((3 -amino-5 -chloropyrazin-2-yl)thio)-2- chlorobenzamide (130 mg, 0.412 mmol) and (R)-2-methyl-N-((R)-8-azaspiro[4.5]decan-l- yl)propane-2-sulfinamide (139 mg, 0.536 mmol) in DIPEA (0.648 mL) was stirred in a microwave reactor for 14 h at 95 °C.
• Step c 3-((3-amino-5-((R)-l-((R)-l,l-dimethylethylsulfinamido)-8- azaspiro[4.5]decan-8-yl)pyrazin-2-yl)thio)-2-chlorobenzamide (65 mg, 0.121 mmol) was dissolved in HCl/dioxane (4 M, 0.121 mL, 0.484 mmol) and stirred at 22 °C until no starting material remained (1 h, monitored by LCMS).
• Step a A mixture of (lR,3R)-ter?-butyl 3-((?er?-butyldimethylsilyl)oxy)-l-((R)- l,l-dimethylethylsulfinamido)-8-azaspiro[4.5]decane-8-carboxylate (100 mg, 0.205 mmol) and HC1 (4 M in dioxane, 510 ⁇ , 2.05 mmol) in MeOH (1 mL) was stirred for 1 h at 40 °C. The volatiles were removed under reduced pressure and the resulting white residue was dried under vaccum for 1 h. MS m/z 171.1 (M+H) + .
• Step b A mixture of this white residue and 3-((2-amino-3-chloropyridin-4- yl)thio)-6-chloropyrazin-2-amine (65 mg, 0.226 mmol) in DIPEA:NMP (2:1 ; 1.5 mL) was vigorously stirred for 40 h at 100 °C. After cooling to RT, the volatiles were removed under reduced pressure and the resulting crude was purified by HPLC (gradient elution 7.5-20%
• Step a A mixture of (3R,4S)-ter?-butyl 4-((R)-l,l-dimethylethylsulfinamido)-3- methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (53 mg, 0.142 mmol) and HQ (4 M in dioxane, 354 ⁇ ⁇ , 1.415 mmol) in MeOH (5 mL) was stirred for 1 h at 40 °C. After cooling to RT, the volatiles were removed under reduced pressure to give (3R,45)-3-methyl-2-oxa-8- azaspiro[4.5]decane-4-amine which was used in next step without further purification. MS m/z 171.1 (M+H) + .
• Step b A mixture of (3R,45)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine crude, 3-((2-amino-3-chloropyridin-4-yl)thio)-6-chloropyrazin-2-amine (35.5 mg, 0.123 mmol), and DIPEA (193 ⁇ , 1.11 mmol) in DMSO (600 ⁇ ) was stirred for 16 h at 100 °C.
• Step a A mixture of (35,45)-?er?-butyl 4-((R)- 1 , 1 -dimethylethylsulfinamido)-3 - methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (51 mg, 0.136 mmol) and HQ (4 M in dioxane, 340 ⁇ ⁇ , 1.362 mmol) in MeOH (5 mL) was stirred for 1 h at 40 °C.
• Step b A mixture of (35,45)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine crude, 3-((2-amino-3-chloropyridin-4-yl)thio)-6-chloropyrazin-2-amine (35.5 mg, 0.123 mmol), and DIPEA (193 ⁇ ,, 1.11 mmol) in DMSO (600 ⁇ ,) was stirred for 16 h at 100 °C.
• Step a A mixture of (lR,3R)-benzyl l-((R)-l,l-dimethylethylsulfinamido)-3- methyl-8-azaspiro[4.5]decane-8-carboxylate (100 mg, 0.246 mmol) and HC1 (4 M in dioxane, 1.5 mL, 6.5 mmol) in MeOH (1.5 mL) was stirred in a microwave reactor for 14 h at 140 °C. After cooling to RT, the volatiles were removed under reduced pressure to give (lR,3R)-3-methyl-8- azaspiro[4.5]decan-l-amine which was used in next step without further purification. MS m/z 169.2 (M+H) + .
• Step b A mixture of (lR,3R)-3-methyl-8-azaspiro[4.5]decan-l-amine crude
• Step a A suspension of (lR,35)-benzyl l-((R)-l,l-dimethylethylsulfinamido)-
• Step b A mixture of (lR,35)-3-methyl-8-azaspiro[4.5]decan-l-amine crude
• Step a A solution of 6-chloro-3-((2-(trifluoromethyl)pyridin-3-yl)thio)pyrazin-
• Step b A solution of l-(6-amino-5-((2-(trifluoromethyl)pyridin-3- yl)thio)pyrazin-2-yl)-4-(aminomethyl)piperidin-4-ol (65 mg, 0.162 mmol) in EtOH (3 mL) was treated in succession with cyanogen bromide (0.541 mL, 1.623 mmol) followed by NaHCC ⁇ (68.2 mg, 0.812 mmol) and the resulting mixture was stirred for 16 h at RT.
• cyanogen bromide 0.541 mL, 1.623 mmol
• NaHCC ⁇ 68.2 mg, 0.812 mmol
• IC 50 is 0.193 ⁇ .
• Step a A mixture of 6-bromo-3-((3-chloro-2-(dimethylamino)pyridin-4- yl)thio)pyrazin-2-amine (124 mg, 0.392 mmol) and (R)-2-methyl-N-((R)-8-azaspiro[4.5]decan-l- yl)propane-2-sulfinamide (111 mg, 0.431 mmol) in DIPEA (2.6 mL) was stirred for 10 h at 90 °C. After cooling to RT, the volatiles were removed under reduced pressure and the resulting residue was purified by silica chromatography (0 to 10% gradient of EtOAc (containing 10% of
• Step b A mixture of (R)-N-((R)-8-(6-amino-5-((3-chloro-2-

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (35)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=52462974

Family Applications (1)

Country Status (42)

Cited By (109)

Families Citing this family (32)

Citations (65)

Family Cites Families (70)

• 2015
  • 2015-01-15 JO JOP/2015/0004A patent/JO3517B1/ar active
  • 2015-01-16 MX MX2016009223A patent/MX356895B/es active IP Right Grant
  • 2015-01-16 DK DK15703321.8T patent/DK3094628T3/en active
  • 2015-01-16 NZ NZ721598A patent/NZ721598A/en unknown
  • 2015-01-16 RS RS20181174A patent/RS57757B1/sr unknown
  • 2015-01-16 BR BR112016016432-6A patent/BR112016016432B1/pt active IP Right Grant
  • 2015-01-16 US US15/110,511 patent/US10077276B2/en active Active
  • 2015-01-16 CR CR20160328A patent/CR20160328A/es unknown
  • 2015-01-16 EA EA201691442A patent/EA031573B1/ru not_active IP Right Cessation
  • 2015-01-16 TN TN2016000268A patent/TN2016000268A1/en unknown
  • 2015-01-16 KR KR1020237005361A patent/KR102688024B1/ko active Active
  • 2015-01-16 ES ES15703321T patent/ES2695242T3/es active Active
  • 2015-01-16 AU AU2015207757A patent/AU2015207757B8/en active Active
  • 2015-01-16 CU CU2016000115A patent/CU24424B1/es unknown
  • 2015-01-16 LT LTEP15703321.8T patent/LT3094628T/lt unknown
  • 2015-01-16 AP AP2016009299A patent/AP2016009299A0/en unknown
  • 2015-01-16 AR ARP150100117A patent/AR100033A1/es active IP Right Grant
  • 2015-01-16 CR CR20200617A patent/CR20200617A/es unknown
  • 2015-01-16 PL PL15703321T patent/PL3094628T3/pl unknown
  • 2015-01-16 SG SG11201605272SA patent/SG11201605272SA/en unknown
  • 2015-01-16 EP EP15703321.8A patent/EP3094628B1/en active Active
  • 2015-01-16 UY UY0001035957A patent/UY35957A/es active IP Right Grant
  • 2015-01-16 PE PE2016001228A patent/PE20170011A1/es unknown
  • 2015-01-16 MY MYPI2016702327A patent/MY176357A/en unknown
  • 2015-01-16 KR KR1020167021977A patent/KR102501558B1/ko active Active
  • 2015-01-16 JP JP2016546839A patent/JP6534389B2/ja active Active
  • 2015-01-16 SI SI201530432T patent/SI3094628T1/sl unknown
  • 2015-01-16 HR HRP20181832TT patent/HRP20181832T1/hr unknown
  • 2015-01-16 CA CA2935695A patent/CA2935695C/en active Active
  • 2015-01-16 HU HUE15703321A patent/HUE039869T2/hu unknown
  • 2015-01-16 MA MA39282A patent/MA39282B1/fr unknown
  • 2015-01-16 WO PCT/IB2015/050345 patent/WO2015107495A1/en not_active Ceased
  • 2015-01-16 PT PT15703321T patent/PT3094628T/pt unknown
  • 2015-01-16 TW TW104101593A patent/TWI657083B/zh active
  • 2015-01-16 CN CN201580004708.7A patent/CN105916845B/zh active Active
• 2016
  • 2016-06-23 IL IL24643616A patent/IL246436B/en active IP Right Grant
  • 2016-07-05 PH PH12016501336A patent/PH12016501336B1/en unknown
  • 2016-07-13 CL CL2016001790A patent/CL2016001790A1/es unknown
  • 2016-07-15 DO DO2016000177A patent/DOP2016000177A/es unknown
  • 2016-07-15 GT GT201600147A patent/GT201600147A/es unknown
  • 2016-07-15 NI NI201600101A patent/NI201600101A/es unknown
  • 2016-07-15 SV SV2016005245A patent/SV2016005245A/es unknown
  • 2016-08-16 EC ECIEPI201667692A patent/ECSP16067692A/es unknown
• 2018
  • 2018-02-20 US US15/899,821 patent/US10336774B2/en active Active
  • 2018-11-08 CY CY20181101177T patent/CY1121155T1/el unknown
• 2019
  • 2019-05-21 US US16/418,978 patent/US10968235B2/en active Active
• 2021
  • 2021-02-23 US US17/182,756 patent/US11952386B2/en active Active
  • 2021-02-23 US US17/182,744 patent/US12209098B2/en active Active
  • 2021-11-22 US US17/532,367 patent/US20220073537A1/en not_active Abandoned

Patent Citations (71)